{"uri":"/api/components/91463","count":53,"data":[{"Synonyms":["PK-10169","CLEXANE","ENOXAPARIN SODIUM SALT [MI]","ENOXAPARIN SODIUM SALT","KLEXANE","ENOXAPARIN SODIUM [WHO-DD]","ENOXAPARIN SODIUM [USP-RS]","ENOXAPARIN SODIUM [HSDB]","ENOXAPARIN SODIUM [MART.]","ENOXAPARIN SODIUM [ORANGE BOOK]","ENOXAPARIN SODIUM [JAN]","ENOXAPARIN SODIUM [USP]","ENOXAPARIN SODIUM [EP]","ENOXAPARIN SODIUM [USAN]","ENOXAPARIN SODIUM [INN]","PK 10169","RP 54563","SODIUM SALT OF A LOW-MOLECULAR WEIGHT HEPARIN OBTAINED BY ALKALINE DEPOLYMERIZATION OF THE BENZYL ESTER OF HEPARIN FROM PORCINE MUCOSA","ENOXAPARIN SODIUM","LOVENOX","RP-54563"],"EVMPD":"SUB11933MIG","ActiveMoieties":"E47C0NF7LV","HSDB":"679809-58-6","INN":"5452","PUBCHEM":"772","LactMed":"679809-58-6","MERCK INDEX":"M4912","WIKIPEDIA":"ENOXAPARIN SODIUM","CAS":"679809-58-6","References":["WEBSITE","ENOXAPARIN SODIUM SALT [MI]","ENOXAPARIN SODIUM [WHO-DD]","ENOXAPARIN SODIUM [USP-RS]","ENOXAPARIN SODIUM [HSDB]","ENOXAPARIN SODIUM [MART.]","ENOXAPARIN SODIUM [ORANGE BOOK]","ENOXAPARIN SODIUM [JAN]","ENOXAPARIN SODIUM [USP]","ENOXAPARIN SODIUM [EP]","ENOXAPARIN SODIUM [USAN]","ENOXAPARIN SODIUM [INN]","SRS import [8NZ41MIK1O]","SRS CODE IMPORT","http://www.news-medical.net/drugs/Clexane.aspx","MERCK","CLINICAL TRIALS","WHO-DD","USP/NF","HSDB","MARTINDALE 2011","ORANGE BOOK 2011","KEGG 2011","USP 33","EP 7.2","USP DICTIONARY 2011","INN 2010","USP DICTIONARY 2008","USP DICTIONARY 2010","FDA_SRS"],"EPA CompTox":"679809-58-6","NCI_THESAURUS":"C75769","ChEMBL":"CHEMBL1201476","Class":"polymer","PreferredName":"ENOXAPARIN SODIUM","id":"8NZ41MIK1O","RXCUI":"221095","UNII":"8NZ41MIK1O"},{"Synonyms":["M-118","ADOMIPARIN [USAN]","ADOMIPARIN","ADOMIPARIN [WHO-DD]"],"ActiveMoieties":"9816XA9004","HSDB":"9005-49-6","LactMed":"9005-49-6","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["WEBSITE","ADOMIPARIN [USAN]","ADOMIPARIN [WHO-DD]","SRS import [9816XA9004]","SRS CODE IMPORT","USP DICTIONARY","WHO-DD"],"EPA CompTox":"9005-49-6","Class":"polymer","id":"9816XA9004","PreferredName":"ADOMIPARIN","UNII":"9816XA9004"},{"Synonyms":["ENOXAPARIN [VANDF]","ENOXAPARIN [WHO-DD]","ENOXAPARIN"],"EVMPD":"SUB21316","LIVERTOX":"351","ActiveMoieties":"E47C0NF7LV","NDF-RT":["N0000007961","N0000175586"],"WHO-ATC":"B01AB05","MESH":"D017984","IUPHAR":"6811","CAS":"9005-49-6","References":["ENOXAPARIN [VANDF]","ENOXAPARIN [WHO-DD]","PubChem 2008","SRS import [E47C0NF7LV]","SRS CODE IMPORT","NDF-RT","WHO-DD","USP DICTIONARY 2008"],"NCI_THESAURUS":"C1452","Class":"polymer","PreferredName":"ENOXAPARIN","id":"E47C0NF7LV","RXCUI":"67108","UNII":"E47C0NF7LV","WHO-VATC":"QB01AB05"},{"Synonyms":["PARNAPARIN SODIUM [JAN]","OP-21-23","OP 21-23","PARNAPARIN SODIUM [WHO-DD]","MINIDALTON","TROMBOPARIN","LOWEPA","FLUXUM","OP-2123","PARNAPARIN SODIUM [INN]","PARNAPARIN SODIUM","PARNAPARIN SODIUM [EP]"],"WIKIPEDIA":"PARNAPARIN SODIUM","CAS":"9041-08-1","EVMPD":"SUB12197MIG","References":["JAN","PARNAPARIN SODIUM [WHO-DD]","PARNAPARIN SODIUM [INN]","PARNAPARIN SODIUM [EP]","SRS import [U6K360XMIU]","SRS CODE IMPORT","CHEMBL","WHO-DD","FDA_SRS","USP DICTIONARY","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER","EP"],"INN":"6317","ChEMBL":"CHEMBL2108080","Class":"polymer","id":"U6K360XMIU","PreferredName":"PARNAPARIN SODIUM","UNII":"U6K360XMIU"},{"Synonyms":["DELIGOPARIN [WHO-DD]","OP2000","OP-2000","DELIGOPARIN SODIUM [WHO-DD]","DELIGOPARIN SODIUM [INN]","DELIGOPARIN SODIUM [USAN]","DELIGOPARIN SODIUM"],"CAS":"9041-08-1","References":["DELIGOPARIN SODIUM [WHO-DD]","DELIGOPARIN SODIUM [INN]","DELIGOPARIN SODIUM [USAN]","USAN;INN","SRS import [R5MB4B485P]","SRS CODE IMPORT","CHEMBL","USP DICTIONARY","WHO-DD","INN","USP DICTIONARY 2011","USP DICTIONARY 2012"],"INN":"8185","ChEMBL":"CHEMBL2109081","Class":"polymer","id":"R5MB4B485P","PreferredName":"DELIGOPARIN SODIUM","UNII":"R5MB4B485P"},{"Synonyms":["HEPARINUM CALCICUM [WHO-IP LATIN]","HEPARIN CALCIUM [WHO-IP]","HEPARIN CALCIUM [VANDF]","ECASOLV","HEPARIN CALCIUM SALT [MI]","HEPARIN CALCIUM [WHO-DD]","HEPARIN CALCIUM [ORANGE BOOK]","HEPARIN CALCIUM [JAN]","HEPARIN CALCIUM [USP]","CALCIPARINE","HEPARIN CALCIUM"],"EVMPD":"SUB02476MIG","ActiveMoieties":"T2410KM04A","WHO INTERNATIONAL PHARMACOPEIA":"HEPARIN CALCIUM","MERCK INDEX":"M5958","CAS":"37270-89-6","References":["HEPARIN CALCIUM [WHO-IP]","HEPARIN CALCIUM [VANDF]","HEPARIN CALCIUM [WHO-DD]","HEPARIN CALCIUM [ORANGE BOOK]","HEPARIN CALCIUM [JAN]","HEPARIN CALCIUM [USP]","USP","SRS import [M4F288ZCTR]","SRS CODE IMPORT","WHO-IP","NDF-RT","MERCK","WHO-DD","ORANGE BOOK 2011","KEGG 2011","USP 33","http://www.drugs.com/international/calciparine.html","USP DICTIONARY 2009"],"ChEMBL":"CHEMBL1201513","Class":"polymer","id":"M4F288ZCTR","PreferredName":"HEPARIN CALCIUM","RXCUI":"20044","UNII":"M4F288ZCTR"},{"Synonyms":["HEPARINUM NATRICUM [WHO-IP LATIN]","HEPARIN SODIUM [WHO-IP]","HEPARIN SODIUM UNFRACTIONATED","HEPARIN SODIUM PORCINE","HEPARIN SODIUM [VANDF]","HEPARIN SODIUM [WHO-DD]","HEPARIN SODIUM, PORCINE","SODIUM HEPARIN [INCI]","LIQUEMIN SODIUM","HEPARIN SODIUM [MART.]","HEPARIN SODIUM [ORANGE BOOK]","HEPARIN SODIUM COMPONENT OF EMBOLEX","EMBOLEX COMPONENT HEPARIN SODIUM","HEPARIN SODIUM [USP]","HEPARIN SODIUM [EP]","HEPARIN SODIUM [INN]","SODIUM SALT OF SULPHATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS","S01XA14","SODIUM SALT OF SULFATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS","SODIUM HEPARIN","LIQUAEMIN LOCK FLUSH","HEPARIN LOCK FLUSH","PANHEPRIN","LIQUAEMIN SODIUM","LIPO-HEPIN","HEPARIN SODIUM"],"EVMPD":"SUB02478MIG","WHO-ESSENTIAL MEDICINES LIST":"10.2","ActiveMoieties":"T2410KM04A","WHO-ATC":["C05BA03","B01AB01"],"INN":"392","WHO INTERNATIONAL PHARMACOPEIA":"HEPARIN SODIUM","CAS":"9041-08-1","References":["HEPARIN SODIUM [WHO-IP]","HEPARIN SODIUM [VANDF]","HEPARIN SODIUM [WHO-DD]","SODIUM HEPARIN [INCI]","HEPARIN SODIUM [MART.]","HEPARIN SODIUM [ORANGE BOOK]","HEPARIN SODIUM [USP]","HEPARIN SODIUM [EP]","HEPARIN SODIUM [INN]","SRS import [ZZ45AB24CA]","SRS CODE IMPORT","WHO-IP","fda_srs","NDF-RT","WHO-DD","FDA_SRS","PCPC","KEGG 2011","MARTINDALE 2011","ORANGE BOOK 2011","Drugs@FDA 2011","USP 33","EP 7.2","INN 2010","FDA-SRS 2010","INN","ORANGE BOOK","USP DICTIONARY 2010"],"NCI_THESAURUS":"C833","ChEMBL":"CHEMBL1201657","Class":"polymer","PreferredName":"HEPARIN SODIUM","id":"ZZ45AB24CA","RXCUI":"9877","UNII":"ZZ45AB24CA"},{"Synonyms":["SEMULOPARIN SODIUM [WHO-DD]","SEMULOPARIN SODIUM [INN]","MULSEVO","VISAMERIN","ULTRA-LOW-MOLECULAR-WEIGHT HEPARIN SODIUM(2000-3000 MW; PHOSPHAZENE DEPOLYMERIZATION)","SEMULOPARIN SODIUM [USAN]","SEMULOPARIN SODIUM","AVE-5026"],"EVMPD":"SUB33017","CAS":"9041-08-1","ActiveMoieties":"4QW4AN84NQ","References":["SEMULOPARIN SODIUM [DASH]","SEMULOPARIN SODIUM [WHO-DD]","SEMULOPARIN SODIUM [INN]","SEMULOPARIN SODIUM [USAN]","USAN;http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03447.x/pdf","SRS import [V5T10N50RD]","SRS CODE IMPORT","WHO-DD","INN","http://www.evaluatepharma.com/Universal/View.aspx?type=Entity&entityType=Product&id=51966&lType=modD","http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03447.x/pdf","FDA_SRS","USAN","http://www.ama-assn.org/resources/doc/usan/semuloparin-sodium.pdf"],"INN":"9035","ChEMBL":"CHEMBL2108718","Class":"polymer","id":"V5T10N50RD","PreferredName":"SEMULOPARIN SODIUM","UNII":"V5T10N50RD"},{"Synonyms":["SEMULOPARIN [WHO-DD]","ULTRA-LOW-MOLECULAR-WEIGHT HEPARIN (2000-3000 MW; PHOSPHAZENE DEPOLYMERIZATION)","SEMULOPARIN [USAN]","SEMULOPARIN"],"ActiveMoieties":"4QW4AN84NQ","MESH":"C569346","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["SEMULOPARIN [WHO-DD]","SEMULOPARIN [USAN]","SRS import [4QW4AN84NQ]","SRS CODE IMPORT","WHO-DD","http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03447.x/pdf","FDA_SRS","USAN COUNCIL"],"NCI_THESAURUS":"C78447","ChEMBL":"CHEMBL2108716","Class":"polymer","id":"4QW4AN84NQ","PreferredName":"SEMULOPARIN","UNII":"4QW4AN84NQ"},{"Synonyms":["CY-216","FRAXIPARINE","NADROPARIN CALCIUM","CY 216","NADROPARIN CALCIUM [WHO-DD]","NADROPARIN CALCIUM [EP]","NADROPARIN CALCIUM [INN]","ULTRAPARINA","SELEPARINA","FRAXIPARINA","FRAXIPARIN"],"EVMPD":"SUB03372MIG","ActiveMoieties":"1K5KDI46KZ","INN":"5750","WIKIPEDIA":"NADROPARIN CALCIUM","CAS":"37270-89-6","References":["NADROPARIN CALCIUM [WHO-DD]","NADROPARIN CALCIUM [EP]","NADROPARIN CALCIUM [INN]","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER","SRS import [LIA7Z4002P]","SRS CODE IMPORT","USP DICTIONARY","WHO-DD","INN","MARCEL DEKKER","FDA_SRS"],"NCI_THESAURUS":"C61320","ChEMBL":"CHEMBL2109204","Class":"polymer","id":"LIA7Z4002P","PreferredName":"NADROPARIN CALCIUM","UNII":"LIA7Z4002P"},{"Synonyms":["HEPARIN SODIUM (BEEF) [VANDF]","HEPARIN SODIUM (BEEF LUNG) [VANDF]","HEPARIN SODIUM BOVINE [WHO-DD]","HEPARIN SODIUM (BEEF)","HEPARIN SODIUM BEEF LUNG","HEPARIN SODIUM BOVINE LUNG","HEPARIN SODIUM BOVINE","HEPARIN SODIUM, BOVINE"],"CAS":"9041-08-1","ActiveMoieties":"P776JQ4R2F","References":["HEPARIN SODIUM (BEEF) [VANDF]","HEPARIN SODIUM (BEEF LUNG) [VANDF]","HEPARIN SODIUM BOVINE [WHO-DD]","SRS import [6DZH9J3B27]","SRS CODE IMPORT","NDF-RT","WHO-DD","rxnorm","FDA_SRS"],"Class":"polymer","id":"6DZH9J3B27","PreferredName":"HEPARIN SODIUM, BOVINE","RXCUI":"236025","UNII":"6DZH9J3B27"},{"Synonyms":["BOVINE HEPARIN","HEPARIN, BEEF","BEEF HEPARIN","HEPARIN BOVINE LUNG","HEPARIN BOVINE","HEPARIN, BOVINE"],"EVMPD":"SUB185273","CAS":"9005-49-6","DRUG BANK":"DB01109","ActiveMoieties":"P776JQ4R2F","References":["SRS import [P776JQ4R2F]","SRS CODE IMPORT","NCT01072955","rxnorm","FDA_SRS"],"Class":"polymer","id":"P776JQ4R2F","PreferredName":"HEPARIN, BOVINE","RXCUI":"1856273","UNII":"P776JQ4R2F"},{"Synonyms":["HEPARIN [VANDF]","HEPARIN [WHO-DD]","HEPARIN [HSDB]","HEPARIN PORCINE INTESTINAL MUCOSA","HEPARIN, PORCINE","HEPARIN [INCI]","HEPARIN [MART.]","SULPHATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS","SULFATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS","HEPARIN"],"EVMPD":"SUB02475MIG","LIVERTOX":"479","ActiveMoieties":"T2410KM04A","ECHA (EC/EINECS)":"232-681-7","NDF-RT":["N0000006341","N0000175980","N0000175474"],"WHO-ATC":["C05BA53","B01AB51","B01AB01","C05BA03","B01AB12","S01XA14"],"MESH":"D006493","IUPHAR":"4214","WIKIPEDIA":"HEPARIN","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["PubChem 2008","SRS import [T2410KM04A]","SRS CODE IMPORT","NDF-RT","WHO-DD","HSDB","FDA_SRS","PCPC","MARTINDALE 2011","FDA-SRS 2010","USP DICTIONARY 2010","USP DICTIONARY 2008","HEPARIN [VANDF]","HEPARIN [WHO-DD]","HEPARIN [HSDB]","HEPARIN [INCI]","HEPARIN [MART.]"],"NCI_THESAURUS":"C539","Class":"polymer","PreferredName":"HEPARIN","id":"T2410KM04A","RXCUI":"5224","UNII":"T2410KM04A","WHO-VATC":["QC05BA03","QB01AB51","QS01XA14","QB01AB01"]},{"Synonyms":["SEVUPARIN [WHO-DD]","DF-02","DF02","SEVUPARIN"],"ActiveMoieties":"7C17NQF03M","References":["SEVUPARIN [WHO-DD]","SRS import [7C17NQF03M]","WHO-DD","FDA_SRS","http://www.dilafor.com/default.asp?headId=46&pageId=46&languageId=2","inn"],"Class":"polymer","id":"7C17NQF03M","PreferredName":"SEVUPARIN","UNII":"7C17NQF03M"},{"Synonyms":["SEVUPARIN SODIUM [WHO-DD]","SEVUPARIN SODIUM [INN]","SEVUPARIN SODIUM"],"CAS":"9041-08-1","ActiveMoieties":"7C17NQF03M","References":["SEVUPARIN SODIUM [WHO-DD]","SEVUPARIN SODIUM [INN]","SRS import [19GW9E1WHN]","SRS CODE IMPORT","WHO-DD","INN","inn"],"INN":"9408","Class":"polymer","id":"19GW9E1WHN","PreferredName":"SEVUPARIN SODIUM","UNII":"19GW9E1WHN"},{"Synonyms":["BEMIPARIN [WHO-DD]","BEMIPARIN"],"EVMPD":"SUB127187","ActiveMoieties":"PUE0TO3XDR","WHO-ATC":"B01AB12","MESH":"C411345","References":["BEMIPARIN [WHO-DD]","SRS import [PUE0TO3XDR]","SRS CODE IMPORT","WHO-DD","Expert Opin Pharmacother. 2003 Sep;4(9):1551-61."],"ChEMBL":"CHEMBL3707365","Class":"polymer","id":"PUE0TO3XDR","PreferredName":"BEMIPARIN","RXCUI":"280611","UNII":"PUE0TO3XDR","WHO-VATC":"QB01AB12"},{"Synonyms":["BEMIPARIN SODIUM [WHO-DD]","BEMIPARIN SODIUM [INN]","BADYKET","ZIVOR","IVOR","HIBOR","BEMIPARIN SODIUM"],"EVMPD":"SUB20549","ActiveMoieties":"PUE0TO3XDR","INN":"7501","CAS":"9041-08-1","References":["BEMIPARIN SODIUM [WHO-DD]","BEMIPARIN SODIUM [INN]","EXPERT OPINION doi:10.1517/14656566.4.9.1551","SRS import [P59JKU02CE]","SRS CODE IMPORT","WHO-DD","Expert Opin Pharmacother. 2003 Sep;4(9):1551-61.","INN"],"ChEMBL":"CHEMBL2108806","Class":"polymer","id":"P59JKU02CE","PreferredName":"BEMIPARIN SODIUM","RXCUI":"436195","UNII":"P59JKU02CE"},{"Synonyms":["M118","ADOMIPARIN SODIUM [INN]","ADOMIPARIN SODIUM [USAN]","ADOMIPARIN SODIUM","ADOMIPARIN SODIUM [WHO-DD]"],"CAS":"9041-08-1","ActiveMoieties":"9816XA9004","References":["ADOMIPARIN SODIUM [INN]","ADOMIPARIN SODIUM [USAN]","ADOMIPARIN SODIUM [WHO-DD]","SRS import [4UTY6300OM]","SRS CODE IMPORT","USP DICTIONARY","INN","WHO-DD"],"INN":"9359","Class":"polymer","id":"4UTY6300OM","PreferredName":"ADOMIPARIN SODIUM","UNII":"4UTY6300OM"},{"Synonyms":"CERTOPARIN","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["FDA_SRS; USP DICTIONARY 2011","SRS import [V72OT3K19I]","SRS CODE IMPORT","FDA_SRS"],"MESH":"C403769","Class":"polymer","id":"V72OT3K19I","PreferredName":"CERTOPARIN","RXCUI":"152610","UNII":"V72OT3K19I"},{"Synonyms":["NADROPARIN [WHO-DD]","NADROPARIN"],"EVMPD":"SUB03371MIG","ActiveMoieties":"1K5KDI46KZ","WHO-ATC":"B01AB06","MESH":"D017762","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["NADROPARIN [WHO-DD]","SRS import [1K5KDI46KZ]","SRS CODE IMPORT","WHO-DD","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER"],"Class":"polymer","PreferredName":"NADROPARIN","id":"1K5KDI46KZ","RXCUI":"67031","UNII":"1K5KDI46KZ","WHO-VATC":"QB01AB06"},{"Synonyms":["CRUDE HEPARIN","CRUDE HEPARIN PORCINE"],"References":"http://www.gpo.gov/fdsys/pkg/FR-2013-06-25/html/2013-15100.htm","Class":"concept","PreferredName":"CRUDE HEPARIN"},{"Synonyms":["CERTOPARIN SODIUM [WHO-DD]","TROPARIN","SANDOPARINE","CERTOPARIN SODIUM [INN]","EMOBLEX-NM","CH-8140","CERTOPARIN SODIUM"],"EVMPD":"SUB20320","ActiveMoieties":"V72OT3K19I","INN":"7194","CAS":"9041-08-1","References":["CERTOPARIN SODIUM [WHO-DD]","CERTOPARIN SODIUM [INN]","SRS import [N816FF9P2W]","SRS CODE IMPORT","WHO-DD","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL;","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL; "],"ChEMBL":"CHEMBL2109012","Class":"polymer","id":"N816FF9P2W","PreferredName":"CERTOPARIN SODIUM","RXCUI":"152612","UNII":"N816FF9P2W"},{"Synonyms":["ARDEPARIN SODIUM [VANDF]","ARDEPARIN SODIUM [WHO-DD]","ARDEPARIN SODIUM SALT [MI]","RD-11885","ARDEPARIN SODIUM [MART.]","ARDEPARIN SODIUM [ORANGE BOOK]","ARDEPARIN SODIUM [INN]","ARDEPARIN SODIUM [USAN]","WY-90493 RD","WY-90493-RD","ARDEPARIN SODIUM","NORMIFLO"],"EVMPD":"SUB00574MIG","ActiveMoieties":"VL0L558GCB","INN":"6985","MERCK INDEX":"M2035","WIKIPEDIA":"ARDEPARIN SODIUM","CAS":"9041-08-1","References":["ARDEPARIN SODIUM [VANDF]","ARDEPARIN SODIUM [WHO-DD]","ARDEPARIN SODIUM [MART.]","ARDEPARIN SODIUM [ORANGE BOOK]","ARDEPARIN SODIUM [INN]","ARDEPARIN SODIUM [USAN]","SRS import [N3927D01PB]","SRS CODE IMPORT","NDF-RT","WHO-DD","MERCK","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL;","MARTINDALE 2011","ORANGE BOOK 2011","INN 2010","USP DICTIONARY 2011","USP DICTIONARY 2009","FDA_SRS","USP DICTIONARY 2010"],"NCI_THESAURUS":"C90877","ChEMBL":"CHEMBL1201448","Class":"polymer","PreferredName":"ARDEPARIN SODIUM","id":"N3927D01PB","RXCUI":"87865","UNII":"N3927D01PB"},{"Synonyms":["ARDEPARIN [VANDF]","ARDEPARIN [WHO-DD]","ARDEPARIN [MI]","ARDEPARIN"],"EVMPD":"SUB00573MIG","MESH":"C093450","MERCK INDEX":"M2035","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["ARDEPARIN [VANDF]","ARDEPARIN [WHO-DD]","ARDEPARIN [MI]","SRS import [VL0L558GCB]","SRS CODE IMPORT","NDF-RT","WHO-DD","MERCK","FDA_SRS"],"Class":"polymer","id":"VL0L558GCB","PreferredName":"ARDEPARIN","RXCUI":"87866","UNII":"VL0L558GCB"},{"Synonyms":["HEPARIN FRAGMENT KABI 2165","DALTEPARIN SODIUM [VANDF]","DALTEPARIN SODIUM (M.R. 4000-6000 D)","DALTEPARIN SODIUM [WHO-DD]","LOW-LIQUEMINE","FRAGMINE","BOXOL","FR-860","KABI-2165","DALTEPARIN SODIUM [MART.]","DALTEPARIN SODIUM [ORANGE BOOK]","DALTEPARIN SODIUM [JAN]","DALTEPARIN SODIUM [EP]","DALTEPARIN SODIUM [USAN]","DALTEPARIN SODIUM [INN]","FRAGMIN","DALTEPARIN SODIUM"],"EVMPD":"SUB11889MIG","ActiveMoieties":"S79O08V79F","INN":"5688","CAS":"9041-08-1","References":["DALTEPARIN SODIUM [VANDF]","DALTEPARIN SODIUM [WHO-DD]","DALTEPARIN SODIUM [MART.]","DALTEPARIN SODIUM [ORANGE BOOK]","DALTEPARIN SODIUM [JAN]","DALTEPARIN SODIUM [EP]","DALTEPARIN SODIUM [USAN]","DALTEPARIN SODIUM [INN]","USP DICTIONARY 2010","SRS import [12M44VTJ7B]","SRS CODE IMPORT","USP DICTIONARY","NDF-RT","swiss medic","WHO-DD","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER","MARTINDALE 2011","ORANGE BOOK 2011","KEGG 2011","EP 7.2","USP DICTIONARY 2011","INN 2010","USP Dictionary 2010","USP DICTIONARY 2008"],"NCI_THESAURUS":"C75767","ChEMBL":"CHEMBL1201460","Class":"polymer","id":"12M44VTJ7B","PreferredName":"DALTEPARIN SODIUM","RXCUI":"82137","UNII":"12M44VTJ7B"},{"Synonyms":["REVIPARIN [WHO-DD]","REVIPARIN"],"EVMPD":"SUB130630","WHO-ATC":"B01AB08","MESH":"C094240","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["REVIPARIN [WHO-DD]","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL;  DEKKER","SRS import [5R0L1D739E]","SRS CODE IMPORT","WHO-DD","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER"],"Class":"polymer","id":"5R0L1D739E","PreferredName":"REVIPARIN","RXCUI":"75960","UNII":"5R0L1D739E","WHO-VATC":"QB01AB08"},{"Synonyms":["REVIPARIN SODIUM [WHO-DD]","CLIVARINE","CLIVARIN","LU-47311","REVIPARIN SODIUM [INN]","REVIPARIN SODIUM [JAN]","REVIPARIN SODIUM"],"EVMPD":"SUB20681","ActiveMoieties":"5R0L1D739E","INN":"6493","WIKIPEDIA":"REVIPARIN SODIUM","CAS":"9041-08-1","References":["SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER","SRS import [5XQ9UBJ16W]","SRS CODE IMPORT","WHO-DD","MARCEL DEKKER","INN","KEGG 2011","MARCEL-DEKKER","REVIPARIN SODIUM [WHO-DD]","REVIPARIN SODIUM [INN]","REVIPARIN SODIUM [JAN]"],"ChEMBL":"CHEMBL2107886","Class":"polymer","id":"5XQ9UBJ16W","PreferredName":"REVIPARIN SODIUM","RXCUI":"75961","UNII":"5XQ9UBJ16W"},{"Synonyms":["TINZAPARIN [VANDF]","TINZAPARIN [WHO-DD]","TINZAPARIN [MI]","HEPARIN [MI]","B01AB10","TINZAPARIN"],"EVMPD":"SUB16468MIG","LIVERTOX":"968","ActiveMoieties":"7UQ7X4Y489","NDF-RT":["N0000007961","N0000175586"],"WHO-ATC":"B01AB10","MESH":"C081247","IUPHAR":"6846","MERCK INDEX":["M5958","M10876"],"CAS":"9005-49-6","DRUG BANK":"DB01109","References":["TINZAPARIN [VANDF]","TINZAPARIN [WHO-DD]","TINZAPARIN [MI]","USP DICTIONARY 2010","SRS import [7UQ7X4Y489]","SRS CODE IMPORT","NDF-RT","WHO-DD","Merck","MERCK INDEX","ATC CODE 2009","FDA_SRS"],"NCI_THESAURUS":"C87297","Class":"polymer","PreferredName":"TINZAPARIN","id":"7UQ7X4Y489","RXCUI":"69646","UNII":"7UQ7X4Y489","WHO-VATC":"QB01AB10"},{"Synonyms":["TINZAPARIN SODIUM","TINZAPARIN NA [VANDF]","TINZAPARIN SODIUM [WHO-DD]","TINZAPARIN SODIUM, PORCINE","LOGIPARIN","LNH-1","LNH1","ENZYME DEPOLYMERIZED HEPARIN (MW 6500)","TINZAPARIN NA","TINZAPARIN SODIUM [MART.]","TINZAPARIN SODIUM [ORANGE BOOK]","TINZAPARIN SODIUM [EP]","TINZAPARIN SODIUM [USAN]","TINZAPARIN SODIUM [INN]","SODIUM SALT OF DEPOLYMERIZED HEPARIN OBTAINED BY HEPARINASE FROM FLAVOBACTERIUM HEPARINUM (HEPARIN LYASE: EC 4.2.2.7) DEGRADATION OF HEPARIN FROM PORK INTESTINAL MUCOSA","INNOHEP"],"EVMPD":"SUB12369MIG","ActiveMoieties":"7UQ7X4Y489","INN":"6764","MESH":"C079002","WIKIPEDIA":"TINZAPARIN SODIUM","CAS":"9041-08-1","References":["TINZAPARIN NA [VANDF]","TINZAPARIN SODIUM [WHO-DD]","TINZAPARIN SODIUM [MART.]","TINZAPARIN SODIUM [ORANGE BOOK]","TINZAPARIN SODIUM [EP]","TINZAPARIN SODIUM [USAN]","TINZAPARIN SODIUM [INN]","SRS import [3S182ET3UA]","SRS CODE IMPORT","WHO-DD","rxnorm","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER","NDF-RT","MARTINDALE 2011","ORANGE BOOK 2011","EP 7.2","USP DICTIONARY 2011","INN 2010","USP Dictionary 2010","USP DICTIONARY 2010"],"NCI_THESAURUS":"C60810","ChEMBL":"CHEMBL1201414","Class":"polymer","PreferredName":"TINZAPARIN SODIUM","id":"3S182ET3UA","RXCUI":"104466","UNII":"3S182ET3UA"},{"Synonyms":["PARNAPARIN [WHO-DD]","PARNAPARIN"],"EVMPD":"SUB22270","WHO-ATC":"B01AB07","MESH":"C080945","CAS":"9005-49-6","DRUG BANK":"DB01109","References":["PARNAPARIN [WHO-DD]","SRS import [M316WT19D8]","SRS CODE IMPORT","WHO-DD","SARRET ET. AL LOW MOLECULAR WEIGHT HEPARIN THERAPY 1999 MARCEL DEKKER"],"ChEMBL":"CHEMBL3707207","Class":"polymer","PreferredName":"PARNAPARIN","id":"M316WT19D8","RXCUI":"69528","UNII":"M316WT19D8","WHO-VATC":"QB01AB07"},{"Synonyms":["DALTEPARIN [VANDF]","DALTEPARIN [WHO-DD]",".ALPHA.-HEPARIN","B01AB04","DALTEPARIN"],"EVMPD":"SUB33617","LIVERTOX":"261","ActiveMoieties":"S79O08V79F","NDF-RT":["N0000175980","N0000175586","N0000007961"],"WHO-ATC":"B01AB04","MESH":"D017985","IUPHAR":"6803","CAS":"9005-49-6","References":["DALTEPARIN [VANDF]","DALTEPARIN [WHO-DD]","USP Dictionary 2010","SRS import [S79O08V79F]","SRS CODE IMPORT","NDF-RT","WHO-DD","stn","ATC CODE 2009","USP DICTIONARY 2009"],"NCI_THESAURUS":"C1453","Class":"polymer","PreferredName":"DALTEPARIN","id":"S79O08V79F","RXCUI":"67109","UNII":"S79O08V79F","WHO-VATC":"QB01AB04"},{"COMPOUND_QCD":["false"],"CompoundName":["HEPARIN"],"CompoundSynonym":["CRUDE HEPARIN","CRUDE HEPARIN PORCINE","EMBOLEX COMPONENT HEPARIN SODIUM","HEPARIN LOCK FLUSH","HEPARIN SODIUM","HEPARIN SODIUM COMPONENT OF EMBOLEX","HEPARIN SODIUM PORCINE","HEPARIN SODIUM UNFRACTIONATED","HEPARIN SODIUM, PORCINE","HEPARINA DE SODIO","HEPARINUM NATRICUM","HÉPARINE SODIQUE","LIPO-HEPIN","LIQUAEMIN LOCK FLUSH","LIQUAEMIN SODIUM","LIQUEMIN SODIUM","PANHEPRIN","S01XA14","SODIUM HEPARIN","SODIUM SALT OF SULFATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS","SODIUM SALT OF SULPHATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS","ГЕПАРИН НАТРИЯ","هيبارين صوديوم","肝素钠","CALCIPARINE","ECASOLV","HEPARIN CALCIUM","HEPARIN CALCIUM SALT","HEPARIN","HEPARIN PORCINE INTESTINAL MUCOSA","HEPARIN, PORCINE","SULFATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS","SULPHATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS"],"CompoundSmiles":["CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]3[C@@H](O)O[C@H](O[C@H]4[C@H](O)[C@@H](OS(O)(=O)=O)C(O)O[C@H]4C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3CS(O)(=O)=O)O[C@@H]2C(O)=O"],"StructureAlert":["true"],"SMILES":"CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]3[C@@H](O)O[C@H](O[C@H]4[C@H](O)[C@@H](OS(O)(=O)=O)C(O)O[C@H]4C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3CS(O)(=O)=O)O[C@@H]2C(O)=O","ChemblId":["CHEMBL1909300"],"KeggId":["D02112"],"Unii":["[ingredient] 2084343018","ZZ45AB24CA","M4F288ZCTR","T2410KM04A"],"ChemSpiderID":["392447"],"Cas":["37270-89-6"],"MOLFILE":"\n  Marvin  11101717090D          \n\n 65 68  0  0  1  0            999 V2000\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n  1  2  1  0  0  0  0\n  2  3  2  0  0  0  0\n  2  4  1  0  0  0  0\n  4  5  1  0  0  0  0\n  5  6  1  0  0  0  0\n  6  7  1  0  0  0  0\n  6  8  1  0  0  0  0\n  8  9  1  0  0  0  0\n  8 10  1  0  0  0  0\n 10 11  1  0  0  0  0\n 11 12  1  0  0  0  0\n 12 13  1  0  0  0  0\n 13 14  1  0  0  0  0\n 13 15  2  0  0  0  0\n 13 16  2  0  0  0  0\n 10 17  1  0  0  0  0\n 17 18  1  0  0  0  0\n  5 18  1  0  0  0  0\n 18 19  1  0  0  0  0\n 19 20  1  0  0  0  0\n 20 21  1  0  0  0  0\n 21 22  1  0  0  0  0\n 21 23  1  0  0  0  0\n 23 24  1  0  0  0  0\n 23 25  1  0  0  0  0\n 25 26  1  0  0  0  0\n 26 27  1  0  0  0  0\n 27 28  1  0  0  0  0\n 28 29  1  0  0  0  0\n 28 30  1  0  0  0  0\n 30 31  1  0  0  0  0\n 31 32  1  0  0  0  0\n 32 33  1  0  0  0  0\n 33 34  1  0  0  0  0\n 34 35  1  0  0  0  0\n 34 36  1  0  0  0  0\n 36 37  1  0  0  0  0\n 37 38  1  0  0  0  0\n 38 39  1  0  0  0  0\n 38 40  2  0  0  0  0\n 38 41  2  0  0  0  0\n 36 42  1  0  0  0  0\n 42 43  1  0  0  0  0\n 42 44  1  0  0  0  0\n 44 45  1  0  0  0  0\n 33 45  1  0  0  0  0\n 45 46  1  0  0  0  0\n 46 47  1  0  0  0  0\n 46 48  2  0  0  0  0\n 31 49  1  0  0  0  0\n 49 50  1  0  0  0  0\n 50 51  1  0  0  0  0\n 51 52  1  0  0  0  0\n 51 53  2  0  0  0  0\n 51 54  2  0  0  0  0\n 49 55  1  0  0  0  0\n 27 55  1  0  0  0  0\n 55 56  1  0  0  0  0\n 56 57  1  0  0  0  0\n 57 58  1  0  0  0  0\n 57 59  2  0  0  0  0\n 57 60  2  0  0  0  0\n 25 61  1  0  0  0  0\n 61 62  1  0  0  0  0\n 20 62  1  0  0  0  0\n 62 63  1  0  0  0  0\n 63 64  1  0  0  0  0\n 63 65  2  0  0  0  0\nM  END\n","Completed":["false"],"id":"HEPARIN"},{"COMPOUND_QCD":["false"],"Pmids":["9875937","9802851","9739898","9570173","9506681","9453569","9380624","9134660","9066940","9034559","8641411","8554694","8280214","8180327","8175046","8016818","7914574","7667822","6233579","3773133","2818066","22118560","21534203","20808689","20739823","20570795","20400762","20160369","19837550","19783545","19522055","19513580","19415734","19357539","19340383","19195684","18786290","18545085","18478950","17764540","17688919","17667218","17549307","17413518","17316348","1723582","17114860","16963663","16924578","16874225","16706967","1660803","16553203","16537665","16510832","1649359","16260867","16243122","16230926","16148626","16123915","16089244","16026400","15457363","15452397","15327525","15299161","15115906","15069410","14979398","14742760","14712967","14597133","1357368","12918901","12741440","12707733","12680483","12222545","12218542","12109865","12020989","11853821","11797033","11776303","11762651","11566456","11505079","11489769","11407108","11402364","11401186","11279659","11251344","11204326","11137723","11136681","11132655","10981327","10069236"],"CompoundName":["ENOXAPARIN"],"CompoundSynonym":["CLEXANE","ENOXAPARIN SODIUM","ENOXAPARIN SODIUM SALT","ENOXAPARINA DE SODIO","ENOXAPARINUM NATRICUM","KLEXANE","LOVENOX","PK 10169","PK-10169","RP 54563","RP-54563","SODIUM SALT OF A LOW-MOLECULAR WEIGHT HEPARIN OBTAINED BY ALKALINE DEPOLYMERIZATION OF THE BENZYL ESTER OF HEPARIN FROM PORCINE MUCOSA","ÉNOXAPARINE SODIQUE","ЭНОКСАПАРИН НАТРИЯ","إينوكسابارين صوديوم","依诺肝素钠","B01AB05","ENOXAPARIN","DEPOLYMERIZED HEPARIN (AVERAGE MW: 4500)","DEPOLYMERIZED HEPARIN OBTAINED BY ALKALIN DEGRADATION","DK-2880","EMT 96","EMT-966","EMT-967","EMT96","ENOXAPARINE","HEPARIN SODIUM, LOW MOL WT 3500-5500","PK 10,16","PK 1016","PK-10,169","PK10,16","PK1016"],"CompoundSmiles":["CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O"],"StructureAlert":["true"],"SMILES":"CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O","ChemblId":["CHEMBL1201685"],"KeggId":["D03674"],"Unii":["8NZ41MIK1O","E47C0NF7LV"],"ChemSpiderID":["29786968"],"Cas":["679809-58-6"],"MOLFILE":"\n  Marvin  11101717150D          \n\n 70 73  0  0  0  0            999 V2000\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n  1  2  1  0  0  0  0\n  2  3  2  0  0  0  0\n  2  4  1  0  0  0  0\n  4  5  1  0  0  0  0\n  5  6  1  0  0  0  0\n  6  7  1  0  0  0  0\n  6  8  1  0  0  0  0\n  8  9  1  0  0  0  0\n  9 10  1  0  0  0  0\n 10 11  1  0  0  0  0\n 11 12  1  0  0  0  0\n 12 13  1  0  0  0  0\n 12 14  2  0  0  0  0\n 12 15  2  0  0  0  0\n  9 16  1  0  0  0  0\n 16 17  1  0  0  0  0\n 17 18  1  0  0  0  0\n 18 19  1  0  0  0  0\n 19 20  1  0  0  0  0\n 20 21  1  0  0  0  0\n 21 22  1  0  0  0  0\n 22 23  1  0  0  0  0\n 23 24  1  0  0  0  0\n 24 25  1  0  0  0  0\n 25 26  1  0  0  0  0\n 26 27  1  0  0  0  0\n 25 28  1  0  0  0  0\n 28 29  1  0  0  0  0\n 29 30  1  0  0  0  0\n 30 31  1  0  0  0  0\n 31 32  1  0  0  0  0\n 32 33  1  0  0  0  0\n 33 34  1  0  0  0  0\n 33 35  1  0  0  0  0\n 35 36  1  0  0  0  0\n 35 37  1  0  0  0  0\n 30 37  1  0  0  0  0\n 37 38  1  0  0  0  0\n 38 39  1  0  0  0  0\n 39 40  1  0  0  0  0\n 39 41  2  0  0  0  0\n 39 42  2  0  0  0  0\n 32 43  1  0  0  0  0\n 43 44  1  0  0  0  0\n 43 45  2  0  0  0  0\n 28 46  1  0  0  0  0\n 46 47  1  0  0  0  0\n 47 48  1  0  0  0  0\n 48 49  1  0  0  0  0\n 48 50  2  0  0  0  0\n 48 51  2  0  0  0  0\n 46 52  1  0  0  0  0\n 23 52  1  0  0  0  0\n 52 53  1  0  0  0  0\n 53 54  1  0  0  0  0\n 54 55  1  0  0  0  0\n 54 56  2  0  0  0  0\n 54 57  2  0  0  0  0\n 21 58  1  0  0  0  0\n 58 59  1  0  0  0  0\n 58 60  1  0  0  0  0\n 18 60  1  0  0  0  0\n 60 61  1  0  0  0  0\n 61 62  1  0  0  0  0\n 62 63  1  0  0  0  0\n 62 64  2  0  0  0  0\n 62 65  2  0  0  0  0\n 20 66  1  0  0  0  0\n 66 67  1  0  0  0  0\n 66 68  2  0  0  0  0\n 16 69  1  0  0  0  0\n  5 69  1  0  0  0  0\n 69 70  1  0  0  0  0\nM  END\n","Completed":["false"],"id":"ENOXAPARIN","Iupac":["6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid"],"CompoundPatent":["7790905","WO2006008173A2","20120108528"],"Cid":["772"]},{"Synonyms":["Parnaparin sodium"],"REFS":["Parnaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","NPC informatics|NPC-9126332|NCGC||","Approved drugs||NCGC||","Structure undefined||NCGC||Structure undefined","Human approved drugs||NCGC||"],"CompoundIndication":["Anticoagulant"],"MOLFILE":"Parnaparin sodium\n  Marvin  11101717262D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Parnaparin sodium","DATASET":["NPC informatics","Approved drugs","Structure undefined","Human approved drugs","Japan"],"SMILES":"","id":"EIH","ID":["EIH"],"URL":["http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list65.pdf"]},{"Synonyms":["Emt 96","Depolymerized heparin obtained by alkalin degradation","Pk1016","Lovenox","Enoxaparine","Pk 1016","Enoxaparin","Enoxaparin sodium","Dk-2880","Pk 10,16","Pk-10169","Depolymerized heparin (average mw: 4500)","Heparin sodium, low mol wt 3500-5500","Clexane","Emt96","Pk-10,169","Pk10,16","Emt-967","Rp-54563","Emt-966"],"CompoundMOA":["Anticoagulants","Fibrinolytic Agents"],"REFS":["Enoxaparin Sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0679809586|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN:BAN|--Name of Substance--","Clexane|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0679809586|USPDDN (United States Pharmacopeia Dictionary of Drug Names)||--Synonyms--","Enoxaparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0679809586|NLM (National Library of Medicine)||--Synonyms--","Enoxaparin Sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0679809586|NLM (National Library of Medicine)||--Synonyms--","Lovenox|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0679809586|Drugs@FDA (FDA Drug Database)||--Synonyms--","679809-58-6|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0679809586|ChemIDPlus||--CAS Registry Number--","Enoxaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","Enoxaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN|--Name of Substance--","Clexane|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","NPC informatics|NPC-9028642|NCGC||","FDA approved||NCGC||","Approved drugs||NCGC||","FDA human approved||NCGC||","Biologics||NCGC||Biologics","Human approved drugs||NCGC||","679809-58-6|ENOXAPARIN SODIUM|KEGG||","ENOXAPARIN SODIUM|LOVENOX|Canada||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM|KEGG||","Enoxaparin sodium|ENOXAPARIN SODIUM|KEGG||","Enoxaparin sodium|Enoxaparin sodium|UK NHS||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM|Tariff||","ENOXAPARIN SODIUM|LOVENOX|FDA orange book||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM (PRESERVATIVE FREE)|FDA orange book||","ENOXAPARIN SODIUM|LOVENOX (PRESERVATIVE FREE)|FDA orange book||","ENOXAPARIN SODIUM|LOVENOX (PRESERVATIVE FREE)|FDA drugs@FDA||","ENOXAPARIN SODIUM|LOVENOX|FDA drugs@FDA||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM (PRESERVATIVE FREE)|FDA drugs@FDA||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM|FDA NDC||"],"CompoundIndication":["Antithrombotic"],"DATASET":["Canada","NPC informatics","KEGG","UK NHS","FDA approved","Approved drugs","FDA human approved","Biologics","FDA orange book","FDA drugs@FDA","Tariff","Human approved drugs","FDA NDC"],"SMILES":"","URL":["http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list52.pdf"],"CAS":["679809-58-6"],"MOLFILE":"Enoxaparin sodium\n  Marvin  11101717272D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Enoxaparin sodium","id":"AYN","ID":["AYN"]},{"Synonyms":["Heparin calcium","Calciparine"],"CAS":["877006-30-9","37270-89-6"],"REFS":["Calciparine|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0037270896|Drugs@FDA (FDA Drug Database)||--Synonyms--","Heparin calcium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0037270896|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","37270-89-6|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0037270896|ChemIDPlus||--CAS Registry Number--","NPC informatics|NPC-9028687|NCGC||","FDA approved||NCGC||","Approved drugs||NCGC||","FDA human approved||NCGC||","Biologics||NCGC||Biologics","Human approved drugs||NCGC||","Heparin calcium|Heparin calcium|UK NHS||","HEPARIN CALCIUM|CALCIPARINE|FDA orange book||","HEPARIN CALCIUM|CALCIPARINE|FDA drugs@FDA||"],"MOLFILE":"Heparin calcium\n  Marvin  11101717272D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Heparin calcium","DATASET":["NPC informatics","UK NHS","FDA approved","Approved drugs","FDA human approved","Biologics","FDA orange book","FDA drugs@FDA","Japan","Human approved drugs"],"SMILES":"","ID":["AVN"],"id":"AVN"},{"Synonyms":["Heparin sodium, porcine"],"REFS":["NPC informatics|NPC-9123267|NCGC||","FDA human approved||NCGC||","FDA approved||NCGC||","Approved drugs||NCGC||","Biologics||NCGC||Biologics","Human approved drugs||NCGC||","HEPARIN SODIUM, PORCINE|HEPARIN SODIUM, PORCINE|FDA NDC||"],"MOLFILE":"Heparin sodium, porcine\n  Marvin  11101717272D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Heparin sodium, porcine","DATASET":["NPC informatics","FDA human approved","FDA approved","Approved drugs","Biologics","FDA NDC","Human approved drugs"],"SMILES":"","ID":["AUY"],"id":"AUY"},{"Synonyms":["Bemiparin sodium"],"REFS":["Bemiparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|NLM (National Library of Medicine)||--Synonyms--","NPC informatics|NPC-9123794|NCGC||","Approved drugs||NCGC||","Human approved drugs||NCGC||","Biologics||NCGC||Biologics","Bemiparin sodium|Bemiparin sodium|UK NHS||"],"CompoundIndication":["Anticoagulant"],"MOLFILE":"Bemiparin sodium\n  Marvin  11101717272D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Bemiparin sodium","DATASET":["NPC informatics","Approved drugs","Human approved drugs","Biologics","UK NHS"],"SMILES":"","id":"AJG","ID":["AJG"],"URL":["http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list75.pdf"]},{"Synonyms":["Cy21","Fraxiparine","Nadroparin","Lmf cy-216","Nadroparine","Heparina","Lmf cy 21","Fraxiparin","Calcium, nadropari","Lmf cy21","Heparine","Cy-216","Nadroparin calcium","Depolymerized calcium heparein obtained by nitrous acid degradation","Cy-216d","Cy 216","Heparinum"],"CAS":["104521-37-1","11078-24-3","11129-39-8","37324-73-5","9005-49-6","9075-96-1","91449-79-5"],"CompoundMOA":["Anticoagulants","Fibrinolytic Agents"],"REFS":["CY 216|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Fraxiparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","Heparina|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Heparina|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)|INN-Spanish|--Synonyms--","Heparine|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Heparine|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)|INN-French|--Synonyms--","Heparinum|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Heparinum|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)|INN-Latin|--Synonyms--","Nadroparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Nadroparine|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","9005-49-6|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|PubMed Toxicology (Toxicology Citations From PubMed)||--CAS Registry Number--","104521-37-1|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Other Registry Number--","11078-24-3|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Other Registry Number--","11129-39-8|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Other Registry Number--","37324-73-5|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Other Registry Number--","9075-96-1|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Other Registry Number--","91449-79-5|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Other Registry Number--","Nadroparin calcium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0037270896|NLM (National Library of Medicine)||--Synonyms--","NPC informatics|NPC-9029245|NCGC||","Approved drugs||NCGC||","Human approved drugs||NCGC||","Biologics||NCGC||Biologics","NADROPARIN CALCIUM|FRAXIPARINE|Canada||"],"CompoundIndication":["Antithrombotic"],"MOLFILE":"Cy21\n  Marvin  11101717272D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Cy21","DATASET":["Canada","NPC informatics","Approved drugs","Human approved drugs","Biologics"],"SMILES":"","id":"AFF","ID":["AFF"]},{"Synonyms":["Fr 86","Heparin sodium, low mol wt 2000-9000","Tinzaparin sodium","Heparin sodium, low mol wt 5500-6500","Fragmin","Deligoparin sodium","Ardeparine sodique","Enoxaparin sodium","Bemiparinum natricum","Enoxaparinum natricum","Fr86","Kabi216","Dalteparin sodium","Liquemin sodium","Tinzaparin","Bristol-myers squibb brand of tinzaparin sodium","Dalteparinum natricum","Sodium, daltepari","Who 31","Ardeparin","Minolteparinum natricum","Pharmacia spain brand of dalteparin sodium","Pharmacia brand of dalteparin sodium","Ardeparin sodium","Deligoparinum natricum","Kabi-2165","Normiflo","Dalteparine sodique","Fr-860","Heparin sodium, low mol wt 500 - 25000","Kabi 216","Ardeparinum natricum","Leo brand of tinzaparin sodium","Dalteparin","Innohep","Depolymerized heparin obtained by peroxide fragmentation","Fragmine","Heparin sodium","Enoxaparine sodique","Wy-90493"],"CompoundMOA":["Anticoagulants","Fibrinolytic Agents"],"REFS":["Ardeparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|NLM (National Library of Medicine)||--Synonyms--","Dalteparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","Enoxaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","Fragmin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)||--Synonyms--","Heparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|Drugs@FDA (FDA Drug Database)||--Synonyms--","Innohep|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|NLM (National Library of Medicine)||--Synonyms--","Normiflo|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|Drugs@FDA (FDA Drug Database)||--Synonyms--","Tinzaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","Ardeparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN|--Name of Substance--","Dalteparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|FDA SRS (FDA Substance Registration System)||--Name of Substance--","Dalteparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN:BAN|--Name of Substance--","Enoxaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN|--Name of Substance--","Heparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|FDA SRS (FDA Substance Registration System)||--Name of Substance--","Heparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN:BAN:JAN|--Name of Substance--","Tinzaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|FDA SRS (FDA Substance Registration System)||--Name of Substance--","Tinzaparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN:BAN|--Name of Substance--","9041-08-1|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|ChemIDPlus||--CAS Registry Number--","101921-26-0|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|TSCAINV (EPA Chem.  Sub.  Inventory)||--Other Registry Number--","102785-31-9|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|TSCAINV (EPA Chem.  Sub.  Inventory)||--Other Registry Number--","12656-11-0|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|TSCAINV (EPA Chem.  Sub.  Inventory)||--Other Registry Number--","Ardeparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Dalteparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Tinzaparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","9005-49-6|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|PubMed Toxicology (Toxicology Citations From PubMed)||--CAS Registry Number--","NPC informatics|NPC-9028739|NCGC||","FDA approved||NCGC||","Approved drugs||NCGC||","FDA human approved||NCGC||","Biologics||NCGC||Biologics","Human approved drugs||NCGC||","9005-49-6|HEPARIN SODIUM|Tariff||","9041-08-1|ARDEPARIN SODIUM|KEGG||","9041-08-1|DALTEPARIN SODIUM|KEGG||","9041-08-1|DELIGOPARIN SODIUM|KEGG||","9041-08-1|HEPARIN SODIUM|KEGG||","heparin sodium|heparin sodium|WHO essential||","HEPARIN SODIUM|HEPARIN SODIUM|KEGG||","Heparin sodium|HEPARIN SODIUM|KEGG||","Heparin sodium|Heparin sodium|UK NHS||","HEPARIN SODIUM|HEPARIN SODIUM|Tariff||","heparin sodium|http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list54.pdf|INN||","HEPARIN SODIUM|EMBOLEX|FDA orange book||","HEPARIN SODIUM|HEPARIN LOCK FLUSH|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM IN PLASTIC CONTAINER|FDA orange book||","HEPARIN SODIUM|HEPARIN SODIUM PRESERVATIVE FREE|FDA orange book||","HEPARIN SODIUM|LIPO-HEPIN|FDA orange book||","HEPARIN SODIUM|LIQUAEMIN LOCK FLUSH|FDA orange book||","HEPARIN SODIUM|LIQUAEMIN SODIUM|FDA orange book||","HEPARIN SODIUM|LIQUAEMIN SODIUM PRESERVATIVE FREE|FDA orange book||","HEPARIN SODIUM|PANHEPRIN|FDA orange book||","HEPARIN SODIUM|SODIUM HEPARIN|FDA orange book||","HEPARIN SODIUM|LIQUAEMIN SODIUM|FDA drugs@FDA||","HEPARIN SODIUM|LIQUAEMIN LOCK FLUSH|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM|FDA drugs@FDA||","HEPARIN SODIUM|LIQUAEMIN SODIUM PRESERVATIVE FREE|FDA drugs@FDA||","HEPARIN SODIUM|PANHEPRIN|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN LOCK FLUSH|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM PRESERVATIVE FREE|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN LOCK FLUSH IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|LIPO-HEPIN|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN LOCK FLUSH PRESERVATIVE FREE|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEP FLUSH KIT IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|SODIUM HEPARIN|FDA drugs@FDA||","HEPARIN SODIUM|HEPFLUSH-10|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|EMBOLEX|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","HEPARIN SODIUM|HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER|FDA drugs@FDA||","Heparin Sodium|Heparin Sodium|Japan||","HEPARIN SODIUM|HEPARIN SODIUM|FDA NDC||","ARDEPARIN SODIUM|ARDEPARIN SODIUM|KEGG||","Ardeparin sodium|ARDEPARIN SODIUM|KEGG||","Ardeparin Sodium|Ardeparin Sodium|USAN||","ARDEPARIN SODIUM|ARDEPARIN SODIUM|Tariff||","ardeparin sodium|http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list68.pdf|INN||","ARDEPARIN SODIUM|NORMIFLO|FDA orange book||","ARDEPARIN SODIUM|NORMIFLO|FDA drugs@FDA||","DALTEPARIN SODIUM|FRAGMIN 5000IU(ANTI-XA)/0.2ML|Canada||","DALTEPARIN SODIUM|DALTEPARIN SODIUM|KEGG||","Dalteparin sodium|DALTEPARIN SODIUM|KEGG||","Dalteparin sodium|Dalteparin sodium|UK NHS||","DALTEPARIN SODIUM|DALTEPARIN SODIUM|Tariff||","dalteparin sodium|http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list64.pdf|INN||","DALTEPARIN SODIUM|FRAGMIN|FDA orange book||","DALTEPARIN SODIUM|FRAGMIN|FDA drugs@FDA||","DALTEPARIN SODIUM|DALTEPARIN SODIUM|FDA NDC||","ENOXAPARIN SODIUM|LOVENOX|Canada||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM|KEGG||","Enoxaparin sodium|ENOXAPARIN SODIUM|KEGG||","Enoxaparin sodium|Enoxaparin sodium|UK NHS||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM|Tariff||","enoxaparin sodium|http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list52.pdf|INN||","ENOXAPARIN SODIUM|LOVENOX|FDA orange book||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM (PRESERVATIVE FREE)|FDA orange book||","ENOXAPARIN SODIUM|LOVENOX (PRESERVATIVE FREE)|FDA orange book||","ENOXAPARIN SODIUM|LOVENOX (PRESERVATIVE FREE)|FDA drugs@FDA||","ENOXAPARIN SODIUM|LOVENOX|FDA drugs@FDA||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM (PRESERVATIVE FREE)|FDA drugs@FDA||","ENOXAPARIN SODIUM|ENOXAPARIN SODIUM|FDA NDC||","DELIGOPARIN SODIUM|DELIGOPARIN SODIUM|KEGG||","Deligoparin sodium|DELIGOPARIN SODIUM|KEGG||","deligoparin sodium|http://whqlibdoc.who.int/druginfo/17_3_2003_proplist89.pdf#page=9|INN||","TINZAPARIN SODIUM|INNOHEP MULTI-DOSE VIAL- 10000 ANTI-XA IU/ML|Canada||","Tinzaparin sodium|Tinzaparin sodium|UK NHS||","tinzaparin sodium|http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list65.pdf|INN||","TINZAPARIN SODIUM|INNOHEP|FDA orange book||","TINZAPARIN SODIUM|INNOHEP|FDA drugs@FDA||","TINZAPARIN SODIUM|TINZAPARIN SODIUM|FDA NDC||","9041-08-1|dalteparinum natricum|INN2||","9041-08-1|enoxaparinum natricum|INN2||","9041-08-1|ardeparinum natricum|INN2||","9041-08-1|bemiparinum natricum|INN2||","9041-08-1|minolteparinum natricum|INN2||","9041-08-1|deligoparinum natricum|INN2||","9005-49-6|heparinum natricum|INN2||"],"CompoundIndication":["Anticoagulant","Antidiarrheal"],"DATASET":["Canada","NPC informatics","KEGG","USAN","UK NHS","FDA approved","Approved drugs","FDA human approved","Biologics","Human approved drugs","INN","FDA orange book","Japan","FDA drugs@FDA","EMA orphan","Tariff","WHO essential","FDA NDC"],"SMILES":"","URL":["http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list65.pdf","http://whqlibdoc.who.int/druginfo/17_3_2003_proplist89.pdf#page=9","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list52.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list64.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list68.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list54.pdf"],"CAS":["9041-08-1","9005-49-6","101921-26-0","102785-31-9","12656-11-0"],"MOLFILE":"Heparin sodium\n  Marvin  11101717272D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Heparin sodium","id":"ADB","ID":["ADB"]},{"Synonyms":["Reviparine","Reviparin-sodium","Heparinum natricum","Heparine sodique","Reviparin","Lu 47311","Alpha hepari","Heparin, sodiu","Clivarine","Lu-47311","Heparin calcium","Who no. 5452","Sodium heparin","Liquaemin","Depolymerized heparin by nitrous acid of heparin from porcin intestinal mucosa","Abbott brand of reviparin-sodium","Clivarin","Reviparin sodium","Heparin","Heparin sodium","Icn brand of reviparin-sodium"],"CompoundMOA":["Anticoagulants","Fibrinolytic Agents"],"REFS":["Clivarin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Clivarine|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Liquaemin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|HSDB (Hazardous Substances Data Bank)||--Synonyms--","Reviparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Synonyms--","Heparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|EINECS (EU Inv of Exist.  Comm.  Chem  Sub)||--Systematic Name--","Heparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|MeSH (Medical Subject Headings File)||--MeSH Heading--","Heparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|HSDB (Hazardous Substances Data Bank)||--Name of Substance--","Reviparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|NLM (National Library of Medicine)||--Name of Substance--","9005-49-6|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009005496|PubMed Toxicology (Toxicology Citations From PubMed)||--CAS Registry Number--","Heparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|Drugs@FDA (FDA Drug Database)||--Synonyms--","Heparinum natricum|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|NLM (National Library of Medicine)||--Synonyms--","Reviparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","Sodium heparin|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|Drugs@FDA (FDA Drug Database)||--Synonyms--","Heparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|FDA SRS (FDA Substance Registration System)||--Name of Substance--","Heparin sodium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0009041081|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN:BAN:JAN|--Name of Substance--","Heparin calcium|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0037270896|RTECS (Reg.  of Toxic Eff.  of Chem.  Sub.)||--Synonyms--","NPC informatics|NPC-9028730|NCGC||","FDA approved||NCGC||","Approved drugs||NCGC||","FDA human approved||NCGC||","Biologics||NCGC||Biologics","Human approved drugs||NCGC||","HEPARIN SODIUM|HEPARIN SODIUM|KEGG||","Heparin sodium|HEPARIN SODIUM|KEGG||","Heparin sodium|Heparin sodium|UK NHS||","heparin sodium|http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list54.pdf|INN||","Heparin Sodium|Heparin Sodium|Japan||","HEPARIN SODIUM|HEPARIN SODIUM|FDA NDC||","HEPARIN|HEPARIN|FDA NDC||","REVIPARIN SODIUM|REVIPARIN SODIUM|KEGG||","Reviparin sodium|REVIPARIN SODIUM|KEGG||","Reviparin sodium|Reviparin sodium|UK NHS||","reviparin sodium|http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list65.pdf|INN||","Heparin calcium|Heparin calcium|UK NHS||","9005-49-6|heparinum natricum|INN2||","heparinum natricum|heparinum natricum|INN2||"],"CompoundIndication":["Anticoagulant","Antithrombotic"],"DATASET":["NPC informatics","KEGG","UK NHS","FDA approved","Approved drugs","FDA human approved","Biologics","INN","FDA NDC","Japan","Human approved drugs"],"SMILES":"","URL":["http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list65.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list54.pdf"],"CAS":["9005-49-6"],"MOLFILE":"Heparin sodium\n  Marvin  11101717272D          \n\n  0  0  0  0  0  0            999 V2000\nM  END\n","name":"Heparin sodium","id":"ABN","ID":["ABN"]},{"Chemical Name":"Heparin, compounds, sodium salt","CAS":"9041-08-0","Raw Materials":"Caustic soda\nHematoporphyrin hydrochloride\nSodium nitrate\nStarch-iodine paper","References":"Lormeau J.-C. et al.; US Patent No. 5,019,649; May 28, 1991; Assigned to\nChoay S. A., Paris Cedex, France","Common Name":["Dalteparin sodium","Tedelparin 4-6"],"UNII PT":"Dalteparin sodium","id":"12M44VTJ7B","Drug Products":"eyJQcm9kdWN0IjoiRnJhZ21pbiJ9\neyJQcm9kdWN0IjoiTGlnb0ZyYWdtaW4ifQ==","UNII":"12M44VTJ7B","Drug Substance":"Dalteparin sodium","Therapeutic Function":"Anticoagulant, Antithrombotic"},{"Chemical Name":"Mucopolysaccaride polysulfuric acid ester","CAS":"9005-49-6","Raw Materials":"Beef intenstine\nChloroform\nHematoporphyrin hydrochloride\nToluene\nWater","References":"Merck Index 4543\nKleeman and Engel p.458\nPDR pp.872, 887, 1286, 1581, 1845, 1949\nI.N. p.481\nREM p.828\nBush, J.A., Freeman, L.D. and Hagerty, E.B.; US Patent 2,884,358; April 28,\n1959; assigned to Southern California Gland Company\nNomine, G., Penasse, L. and Barthelemy, P.; US Patent 2,989,438; June 20,\n1961; assigned to UCLAF, France\nToccaceli, N.; US Patent 3,016,331; January 9, 1962; assigned to\nOrmonoterapia Richter SpA, Italy","UNII PT":"Heparin","id":"T2410KM04A","Drug Products":"eyJDb3VudHJ5IjoiVVMiLCJQcm9kdWN0IjoiSGVwYXJpbiIsIlllYXIgSW50cm9kdWNlZCI6IjE5NDIiLCJDb21wYW55IjoiVXBqb2huIn0=\neyJDb3VudHJ5IjoiVVMiLCJQcm9kdWN0IjoiSGVwcmluYXIiLCJZZWFyIEludHJvZHVjZWQiOiIxOTc2IiwiQ29tcGFueSI6IkFybW91ciJ9\neyJDb3VudHJ5IjoiSXRhbHkiLCJQcm9kdWN0IjoiQ2hlbXlwYXJpbiIsIkNvbXBhbnkiOiJTLkkuVC4ifQ==\neyJDb3VudHJ5IjoiSXRhbHkiLCJQcm9kdWN0IjoiQ2xlYXJhbmUiLCJDb21wYW55IjoiSmFtY28ifQ==\neyJDb3VudHJ5IjoiSXRhbHkiLCJQcm9kdWN0IjoiRGlzZWJyaW4iLCJDb21wYW55IjoiVHViaSBMdXggUGhhcm1hIn0=\neyJDb3VudHJ5IjoiVVMiLCJQcm9kdWN0IjoiRW1ib2xleCIsIkNvbXBhbnkiOiJTYW5kb3oifQ==\neyJDb3VudHJ5IjoiVVMiLCJQcm9kdWN0IjoiRW5kb3ByaW4iLCJDb21wYW55IjoiRW5kbyJ9\neyJDb3VudHJ5IjoiSXRhbHkiLCJQcm9kdWN0IjoiRXBhcmluYSIsIkNvbXBhbnkiOiJWaXN0ZXIifQ==\neyJDb3VudHJ5IjoiSXRhbHkiLCJQcm9kdWN0IjoiRXBhcmlub3JhbCIsIkNvbXBhbnkiOiJCcnVjbyJ9\neyJDb3VudHJ5IjoiSXRhbHkiLCJQcm9kdWN0IjoiRXBhcmlub3ZpcyIsIkNvbXBhbnkiOiJWaXMifQ==\neyJDb3VudHJ5IjoiVVMiLCJQcm9kdWN0IjoiRmlvcmljZXQiLCJDb21wYW55IjoiU2FuZG96In0=\neyJDb3VudHJ5IjoiVy4gR2VybWFueSIsIlByb2R1Y3QiOiJIYW1vY3VyYSIsIkNvbXBhbnkiOiJOb3JkbWFyayJ9\neyJDb3VudHJ5IjoiVUsiLCJQcm9kdWN0IjoiSGVwYWNvcnQgUGx1cyIsIkNvbXBhbnkiOiJSb25hIExhYnMifQ==\neyJDb3VudHJ5IjoiU3dpdHouIiwiUHJvZHVjdCI6IkhlcGEgR2VsIiwiQ29tcGFueSI6IlNwaXJpZyJ9\neyJDb3VudHJ5IjoiVy4gR2VybWFueSIsIlByb2R1Y3QiOiJIZXBhcmluLVBvcyIsIkNvbXBhbnkiOiJVcnNhcGhhcm0ifQ==\neyJDb3VudHJ5IjoiSmFwYW4iLCJQcm9kdWN0IjoiSGVwYXJpbiBTb2RpdW0iLCJDb21wYW55IjoiVG9reW8gVGFuYWJlIn0=\neyJDb3VudHJ5IjoiSmFwYW4iLCJQcm9kdWN0IjoiSGVwYXJpbmluIiwiQ29tcGFueSI6IlNhbmt5byJ9\neyJQcm9kdWN0IjoiSGVwYXRocm9tYiJ9\neyJQcm9kdWN0IjoiSGVwLUxvY2sifQ==\neyJQcm9kdWN0IjoiSGVwc2FsIn0=\neyJQcm9kdWN0IjoiTGlxdWFlbWluIn0=\neyJQcm9kdWN0IjoiTWluaWhlcCJ9\neyJQcm9kdWN0IjoiUGVyY2FzZSJ9\neyJQcm9kdWN0IjoiUHJhZWNpdmVuaW4ifQ==\neyJQcm9kdWN0IjoiUHVsYXJpbiJ9\neyJQcm9kdWN0IjoiVGhyb21iYXJlZHVjdCJ9\neyJQcm9kdWN0IjoiVGhyb21iby1WZXRyZW4ifQ==\neyJQcm9kdWN0IjoiVGhyb21vcGhvYiJ9","UNII":"T2410KM04A","Drug Substance":"Heparin","Therapeutic Function":"Anticoagulant"},{"toxicity":"Symptoms of overdose may include excessive bleeding and bruising.","mechanism-of-action":"Ardeparin binds to antithrombin III, accelerating its activity in inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity versus anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.","pharmacodynamics":"Ardeparin, an anticoagulant, is a fractionated heparin. It acts at multiple sites in the normal coagulation system to inhibit reactions that lead to the clotting of blood and the formation of fibrin clots both <i>in vitro</i> and <i>in vivo</i>.","description":"blood coagulation","groups":["approved","withdrawn"],"half-life":"Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.","unii":"VL0L558GCB","drugbank-id-others":["APRD00803"],"xml":"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","name":"Ardeparin","metabolism":"Liver and the reticulo-endothelial system are the sites of biotransformation.","id":"DB00407","indication":"For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.","drugbank-id":"DB00407"},{"toxicity":"In mouse, the median lethal dose is greater than 5000 mg/kg. Another side effect is heparin-induced thrombocytopenia (HIT syndrome). Platelet counts usually do not fall until between days 5 and 12 of heparin therapy. HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors. It can progress to thrombotic complications such as arterial thrombosis, gangrene, stroke, myocardial infarction and disseminated intravascular coagulation. Symptoms of overdose may show excessive prolongation of aPTT or by bleeding, which may be internal or external, major or minor. Therapeutic doses of heparin give for at least 4 months have been associated with osteoporosis and spontaneous vertebral fractures. Osteoporosis may be reversible once heparin is discontinued. Although a causal relationship has not been established, administration of injections preserved with benzyl alcohol has been associated with toxicity in neonates. Toxicity appears to have resulted from administration of large amounts (i.e., about 100–400 mg/kg daily) of benzyl alcohol in these neonates. Its use is principally associated with the use of bacteriostatic 0.9% sodium chloride intravascular flush or endotracheal tube lavage solutions.","mechanism-of-action":"Under normal circumstances, antithrombin III (ATIII) inactivates thrombin (factor IIa) and factor Xa. This process occurs at a slow rate. Administered heparin binds reversibly to ATIII and leads to almost instantaneous inactivation of factors IIa and Xa The heparin-ATIII complex can also inactivate factors IX, XI, XII and plasmin. The mechanism of action of heparin is ATIII-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Heparin is not a thrombolytic or fibrinolytic. It prevents progression of existing clots by inhibiting further clotting. The lysis of existing clots relies on endogenous thrombolytics.","synonyms":["Calciparine","Eparina","Heparinate","Heparinic acid","Liquaemin","Panheprin","Unfractionated heparin"],"pharmacodynamics":"Unfractionated heparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3000 to 30,000 daltons. Heparin is obtained from liver, lung, mast cells, and other cells of vertebrates. Heparin is a well-known and commonly used anticoagulant which has antithrombotic properties. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Small amounts of heparin in combination with antithrombin III, a heparin cofactor,) can inhibit thrombosis by inactivating Factor Xa and thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin prolongs several coagulation tests. Of all the coagulation tests, activated partial prothrombin time (aPTT) is the most clinically important value.","description":"regulation of hair follicle development","groups":["approved","investigational"],"half-life":"1.5 hours. \r\n\r\nThe plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose. ","unii":"ZZ45AB24CA","drugbank-id-others":["APRD00056"],"route-of-elimination":"The drug appears to be removed mainly by the reticuloendothelial system. A small fraction of unchanged heparin also appears to be excreted in urine. Heparin cannot be eliminated by hemodialysis.","xml":"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","name":"Heparin","clearance":"Adult Clearance = 0.43 ml/kg/min\r\n25-28 weeks gestation = 1.49 ml/kg/min","metabolism":"Liver and the reticulo-endothelial system are the sites of biotransformation. The metabolic fate of heparin is not well understood. ","id":"DB01109","indication":"Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.","drugbank-id":"DB01109"},{"toxicity":"Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors.","mechanism-of-action":"The mechanism of action of enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa.","synonyms":["Enoxaparin sodium"],"pharmacodynamics":"Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3800 to 5000 daltons. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of enoxaparin in combination with antithrombin III (enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH. ","groups":["approved"],"description":"respiratory burst involved in defense response","SMILES":"CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O","half-life":"4.5 hours","unii":"8NZ41MIK1O","InChIKey":"HTTJABKRGRZYRN-UHFFFAOYSA-N","drugbank-id-others":["APRD00068"],"route-of-elimination":"Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.","xml":"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","name":"Enoxaparin","metabolism":"Undergoes desulfation and polymerization via the liver","id":"DB01225","indication":"For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.","drugbank-id":"DB01225"},{"toxicity":"Overdosage: hemorrhagic complications. \r\nAdverse Drug Reaction: \r\n(common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia. \r\n(uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema","mechanism-of-action":"Dalteparin potentiates the activity of ATIII, inhibiting the formation of both factor Xa and thrombin. The main difference between dalteparin and unfractionated heparin (UH) is that dalteparin preferentially inactivates factor Xa. As a result, only a slight increase in clotting time [(i.e. activated partial thomboplastin time (APTT)] is observed relative to UH. For this same reason, APTT is not used to monitor the effects of dalteparin except as an indicator for overdosage. ","synonyms":["alpha-heparin"],"pharmacodynamics":"Dalteparin has an antithrombin binding site that is essential for high affinity binding to the plasma protein antithrombin (ATIII). Anti-Xa activity of plasma is used as both as an estimate of clotting activity, and as a basis to determine dosage. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH. ","description":"regulation of hair follicle development","groups":["approved"],"half-life":"Terminal Half life:\r\nIntravenous - 2 hours. Subcutaneous - 3-5hours","unii":"12M44VTJ7B","route-of-elimination":"After 4 hours, about 20% is seen in urine. Most of the remainder is found in the liver, gastrointestinal tract and kidney. The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).","xml":"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","name":"Dalteparin","clearance":"Excreted via kidneys. The plasma clearance rate is 33 mL/min.","metabolism":"Liver and the reticulo-endothelial system are the sites of biotransformation. They are partially metabolized by desulphatation and depolymerization.","id":"DB06779","indication":"Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. \r\n\r\nDalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).\r\n\r\nIt is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.","drugbank-id":"DB06779"},{"toxicity":"Osteoporosis with increasing duration of use, bleeding, alopecia, heparin induced thrombocytopenia (HIT). All of these adverse drug reactions occur less with LMWH compared to unfractionated heparin. Tinzaparin showed no toxic effects at doses up to 5 mg/kg in mice, rats, or dogs in standard acute, subacute, and chronic toxicity studies.","mechanism-of-action":"Tinzaparin binds to the plasma protein antithrombin III, forming a complex with then accelerates the inhibition of factor Xa. Its affinity for factor Xa is 2-4 times greater than that of unbound ATIII. The inactivation of factor Xa in turn will exponentially generation of thrombin (factor IIa) molecules, which is needed to activate fibrinogen to fibrin. The coagulation cascade is inhibited because fibrin cannot be formed in the presence of tinzaparin. Like all LMWH, it cannot be given intramuscularly due to increased risk of hematoma.","synonyms":["Tinzaparin sodium"],"pharmacodynamics":"Tinzaparin, like other LMWHs, have a higher anti-Xa activity  than anti-IIa activity. The anti-Xa activity of tinzaparin is 2.0 +/- 0.5 times greater than its to anti-IIa activity. Heparin exhibits approximately equal inhibitory activity against Xa and IIa. Tinzaparin is an anticoagulant that blocks the formation of thrombi. Like all LMWHs, tinzaparin only causes activated partial thromboplastin time (aPTT) prolongation at higher doses and routine monitoring is not recommended. However, anti-factor Xa levels may be monitored in some conditions such as pregnancy and renal dysfunction. Its use should be avoided in patients with a creatinine clearance less than 20 mL/min. In these patients, unfractionated heparin should be used. Tinzaparin can be used in patients who have a creatinine clearance between 20-30 mL/min, giving it the highest safety threshold for use in renal failure patients compared to all the LMWHs.","description":"defense response to bacterium","groups":["approved"],"half-life":"Anti-Xa activity is 82 minutes. Anti-IIa activity is 71 minutes.","unii":"3S182ET3UA","route-of-elimination":"Linear elimination through kidneys","xml":"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","name":"Tinzaparin","clearance":"Clearance is dose-dependant. The clearance of tinzaparin based on anti-Xa activity ranged from 1.14 to 2.04 L/hr","metabolism":"Sulfation and polymerization occurs in the liver.","id":"DB06822","indication":"Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.","drugbank-id":"DB06822"},{"toxicity":"Osteopenia with extended use, skin necrosis, thrombocytosis, severe immunologically-mediated thrombocytopenia, eosinophilia (rare), calcinosis rarely occurs at the injection site, severe bleeding, transient elevation of liver transaminases.","mechanism-of-action":"The mechanism of action for nadroparin is similar to all other LMWHs. Like all LMWHs, nadroparin has a pentasaccharide sequence which binds to ATIII, which potentiates the action of ATIII. This complex greatly accelerates the inactivation of factor Xa and factor IIa. As a result, the coagulation cascade is inhibited.","pharmacodynamics":"Nadroparin is a low molecular weight heparin that is composed of a heterogeneous mixture of sulfated polysaccaride glycosaminoglycan chains. Th mean molecular weight is approximately 4300 daltons. The ratio of anti-Xa activity to anti-IIa is 3.5:1 whereas it is about 1:1 for heparin. Its use should be avoided in patients with a creatinine clearance less than 40mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH. ","description":"response to gamma radiation","groups":["approved"],"half-life":"In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.","unii":"LIA7Z4002P","route-of-elimination":"Nadroparin is eliminated via the kidneys through non-saturable mechanisms.","xml":"eJztfWuT2rqy6Hd+hb/ce5K6w4Q3Q1YqVY4BDwtDDPYme9atW6eM0QzeMTbLj8mQ2j/+dkuyMTOMmDy80Non65GAaUvdrVarpX7o3SpK795XFOUdflg6weeqt3rf/1C7uqo3370pPkSgwNmQ91NnFYVbJ/KCd2/oA/o6id3I2yZeGBQAFC9WHMUPvyib0Cdu6juR8oV4d+tEWRMG8cqYfLp+rXxZe+76Av4igbIM02ClJKHiBImXrKNwswTA0WikvFJt+Ov1heK4LvFJ5CQkVpI1UbzAcRPv3sH+lfBWuYWvYQTvQBur7Ns/nUulgNva8RP2ths6d4AbfXnrJOsvzk5Z7qDRtbf0Ei+4o1CHPeR4vcr7cl7jW4XObHxrs/W9W88tvEiUW2+JGLh+mNDmXSd2nRVBdsVJuN2SlRIGLuFtxdAYpQO6UJyoQC1ZXSqjBF9bkci7h9duAStlG0auFxAlDtPIBQ7hu2sHh2JDnKAwFrH3lSBO7VqtpqyAH2EQXyqGYLxiioBP4lght7cE0QAak8IAADl7jiirlOBIAtEedLcOo4RE8Hpwl6yB7Rtok9ChToPbCFsIA6Qq6+0SRLAgWChowKpqkG6WJHrfq7Xq1dpVtf7uTeEpAqWB572vj9vj/qjVGf/x7g19gL/ECbT/Pg59b/XuDfuCj++iMN3G+DH78t7ZbqMQWPruDfuOYG/2cO/uSAAC6FcjcksiAqOVve5Eief62df9g+w7PNmmyw1Z4azqtnrtWhco2D/ag7leQsXmvRb6vncXgAANL5RhtFttYBjVC0Vztr4DgnR9oXz8GqYPysS4UAyizPHzzYXyIUyTtQcc//0ChXHppH6i/P77W0WjrPfivUhu1060cdzwMwgOoKsA8bceUMFlnZBH03jjgAhkQlGtovCwLxcKCcIHh80xlLwgn3LVqrPaeIEXgxDAIMfp0k0TJyBhGvs43aA9aGa9U+5DPw0SQkD0X63CGLC4BXnaRuSeBIcTMCTwv+/Fm9c43fCJcu2QTRgnl0q912sr6jb6rdt81Xr9ttOsVVs1EKmcrdkAvXk0QsIRu+rCeHXaJ0YsH6S3OJ2qOd+qj6bTW2CRAmIW3XvkCx8LmCnZaKx2oGE9N754PD5sUm9I4jDyKfdS6BHmL2eAE3sxZULnt0ZHsdLt1lcabxutavPqh5nQq7evGvXaCSYYjqeMpxfKJweUggryeB0q4wvF+kpgxmsaiKqnTODnEH424IebVFE/vVX+EVOlBPJWxcEXrx9UajbhynP8HSVY3Si/K2NvFZCd0s84oEzD+98aV6/ar992G/Vq58cZ0Oo121fdEwz4EAYkVT5cwLJz70QREI1zdrNMY+V382D6rv5L/Uo2QB48nhLX9YA4nLX9NCIJBdaddIXvWx5RzLeK+UhCqDwkIS6KuHKgJH0JC3MPZ9CGL3Iwq+q1i0a7Rl9q1C5A/9PFFhea0T+UB2Xjv6rWX7+GZcUHBY+TFSdgHReJXYz6HsQ0crYkRVWBg3R09l0pQ7L8rdt71Xj9ttm8qrbqP8z3eg3ErttsnZS8LS41inWhTGB2EFhmkbOm92cK7IRP/TBd4hIJAHaYuuswQX3aJy7oIhida2BwuM1tgke6EZhbYKzr+K6XbpRXw8h58Ogz8hrl0l17/gqWBmUdxlvADOYpZ2S4JVTZRQkoweiORLtLZZCCmmbDqliuRxnYUybO7rcr5F+93qs22j/Ov0an0b1qd07wb3qnXP+OSwlRDODFNZtsVS9YpS4u2Ez3ursEKfEc0GLu5yD84pPVHRoAHhhWoK1jXBaRE35RBT6ewUyUgAOjACQd+to4IMeXIJe1JhOgLmXAVbva/XH667V6/ap2iv4PIPIrnJljEAQY6PXOh7HlkywiTrKBhQjlYEXItnpPKBmUJ1QHWQSWuXxG8AkB9NT2mrj+ttWtths/YUDbzU6zfcqCuHbA/rOAmgWszml8uHq6CpgCnylxfOSyddYrCO9XggvOCkxZH61kD0AEpDZwMqHK7bx+2+52q1etn7Do1K56vVOLTt+5h4Gag50E1s4qVvpvi0Y/n6ywTChAJV9zKdF8jvvh3Y5ywvXBUkFa05jKMDWS9px5IgmPOLoC4yoCqxxY1IddVKyoODPorO5So6ReQ6Ok0etVm42fIQYwqxsn5XoE9vbGXaefFXXkXCh/hEl4r6igBLU1ifHxYnChqIH3OXX/63OoTMHc/MP5DKxJYnLvKAas1n0PjGZfmSwulHHk3LuwYwNIFb4aIewVQwD7OMBlagW7EGzy4+it8n+1jJv5riHAPcRxTcq5jaqRvnPA5yV8iROABd0S/b9LZRFuI+Uj4MBVxm8tut40au3qj9s50GC93Ws2T7B1gROEKENgwhxYGqxCXFgsoNBRKEPhGQETXtGB0yAegUNXI7TAPVx3dM/ZhAq8PSRR5KTK8C1oCdjixvFt6iuZ0Rzle0i2p6bGEXzL2FbgpBfkUxTYCCyP6L6Mbg5TfwO7rGinZKYzleVlhJYIGpRoORI0TGGG4Cqa2RIuPr4EDf0xgGnCVyoTd23I+Hpd+T0NfqszXQ0bs9YlIOi9BaPhsl7vdt/Asn1Vb4OMguHUbHXasOIBT3HIeqgqlPqPG2X1XheWt8apSaDe5YOhpzHsgejHDx5I1BoYjUbWAiZuiLbpBHjj+A5+1MCGC2DkYIv1wYkADobYcJb4moP65kP69auHGzTLBRPPc7BRE3ZJ8Lr7Z0pB5h5Ydvie7sR0oGjPRhghGjj+YDB6X78iRgM0TGAzDFgcKDA0Hx6poqfKh/4UoxSgsQlWTAjDnQvEFw8233ykqTkDO/IQhAj2YM7qHucV7M1wh8wnGciBS7x7elCBtjZfsKmEAHvCDdo1sEMBOskyrLphkESwYcVnKzCzfFJdgshDm0m6gmXewEYTJkWXbPw/ugnqw3rt9dteq1ntFUSnVu+8seqtbq3aqLXar2q9191ao9moNovyo6Z3SvMFxmX+NdurJ+QhWYbh5/j9uzf7z+w3wJk+Z3+z7f/RPf+7eBcAT2Dl3/8A7x17itDACn4c9OikLM3Mw23B4hCsLHTecpQyOxLHHObsGuwy6CV7evHUaFEeGS0XjyQqP5tapVR3FDdZTxe/NABZgpGGX+5Qu9F9fxhUZ8oX554omx3IV4SvA363TkQPet69KXACGfN40/ttB4nJ2qEnYXiqFCInqZ5ck4REITIJrZ6N95DAhgp/ilP/lh41bUOgyXEBP29FlDt/54YxdB+E+NFBKx4UY4z7m8enZxwBRA3Pih68Da6MO6XVLJ6m4SEg1dwUIeBvFU/zcAn0kl12ylnFszJoqHnZflvHU1Bc5MAuoY0vwzQBe7FOZSM7GVNGCZUYPFQDO0dZAu/vQyBhdaD86Vx3FBcHC9QN7HhA+h22R6SneMC2QGnVNsabDW2VLr3QbNbCxTNHc1m/YQAUQ+covGBVsZMaWGA80DkgNxeMVGwPZh6u5UziQFnECY6atyHKK8e07deAq++z9rwAEY7pyeIamKywQyB2KCA4m2SHyZTnMOfCiFwUUFGwF2RoAJs9UGnhBqR3hVhfh19A9KOLp8ODAgDEwcDDTGInlbxBqoTBmAEBdnfZIRp2fwl64okko3hvCIgSrOObanhbZQx9j8KRP6cCQp9TJgYH0h97Gw9JRoFBNqESpv3hga33mdCn9PtF8U127AubNND2IORrJuUxgX0wigA9dldgJwyGMrRMj9cv+NNtmKA6yM/YOWqAJAVDLvPp5pMH5Q4lDFeQl53M8xPt/UkxlR00OWBiJhdPjuULJ+T8WB4G7t2bYzxFXicwG2Et2L3/GCeE7VHZVAAdTwcd5fVCiWFHrwTEjZgGLGxr6fcYpQL63GzSADcGHl0kq7gJolPh8Tb4QiHwYgDK2/Ohw1cRWNuvL5h9FmCTCj4BJoWum0bZOQoQ9C/CeBsDWXm3oE6hI5xCYPkFMc5GBVi7ZyU9mmE/osKi5hksYxnpTOayA8JHyjT74SvTF4gGbY7yNH8Hm3CWsNyw83c1/4hNwLoImoQpuKUXgnUEAroEypPdI7veucVT/+Jx72ObNldzV73/BSgU+kQU1o5/W/W9W/J+tD8j3isoRB5BFATBppYk+UJIgNp0HVHBrtcvG/jxFuyS8AsqAwE2gMC+R7owRTAVvKCK8wTefT9JYXpAO0BU0Yexzg7A2fzBqYcnu0qv9r8U3gTzbUEHj5vEbiJgAEFBJr6H43nERMh+gQ7vQcKQ8s/0qJPt6FNQlbjsxg4sc3Q9zicIisbRDrBnPG/f0F9WyAVvmdKfgH89492bZ36l3phsMaGabL+0HI4/IN6oX7aU//OmqnQv+VoDxlr+MjWi0B3HTS/8nJtwh55JSzVs2JTVm+0n7kkK/chFmW2O9q5KCkX9QcZI7f7RqtUa5t5BxHYKe29Ss9sA0/OqV+08djJRSA+3DJ/J7j0aM/wjtzQzGtin3FAMg90mZtYh+8gFbJW6Ofn86yFNhdPFR8TArIP9DGClxniuyE+G0U+nOTAKDizqLox+DpY3u3KRc9Aa+1B8zlEAY35FOMTBo3xwtnSXVWs0mp0edRlvi9su9LdFIK3VjRN9JmhPVkFy8Gi4WmtUa23qg3sKkL1NVfXhT+/eHHmYYwOm2x2p4lH3ewuklpmZxad7vCLqhHzfw7NvGP0EUeHPMiA6X0DngF64p8dmv8G2fK82+ITKwW9XThUsQZ/btJmsvHvzzA/Ze9SE99z3t44fE77JgK/Zz6hDqjDTgfHoFIsyuCfP8y0y91y+T6IU4PKvuXgjfLR7z6QD5Jp/z3lD3cbv+2YfeMI+c5k+EMy/pZi22rVOvf1LTH+JqfRi2vilTX+Jqfxi2qz/EtNfYiq9mLavfonpLzHNxVQZYnyIjMLaaMHutvViYe1Va51qo3F+Ya33ar+k9X+ctKJq7XR+Sesvaf27SGv3l279nyOt+Rd2zuohBuzc2/GrS4xeiOnR7ZHHCM/9xdm5LP/6UtsXxj0iK+qkOEiaKT7nKB+0fLKfoxOstN5+9SN3P3+tNPzE3vIv3AniuJ9BBUY4I/ef6TR0ghQ9xQBKfz38Tt8FVUToi+wDPgM1Ru7CyMunL3+wVyH5AzVIPO5tBlTR0/MIckPiNfU/gR7uNdroJGUPOFWHLwh6+uCH4Yq6vtkn4OYG3ZEfozsnEPX8/V1qTrQM17sV9cmLaYPNR/2HOlp54b0Ts+AM9Y6cZGajWe/+QIdrsqEBoqrL0hqQr/+IT1DZqNU7re/vdMhy9yawrPgs3e0FhLZrjV7vR/sM/R2G672Er+1mq/n93emPg6BO9Nap/ciU4AH/GF7xIto6sEH+kd64bhJ30fsB9l3nqa3hF5CTLFjpEw1Wel3KHM+61DE/scweLmg6W05UlRF1kps/IB57Bk7yWAaMLzD3AfsFHSDEpNVu135g5h/0mOmcE6qm0bj6gQ55aCKL2hJ3Va/Xmz9Am13I5zqpQZGPHWFf+Te++r5zaNg/bIlCXOhwDEEWjzys5BukbNVm3/bbl8Nt08F+6Rt3QqfPWbNt2V+HyvM7vSIu2WfO28Sl+908AZl/z1v3yT3xcx1xx3QEe3gIok7tkX09/zj58NEeaYqqD6a29cOgH4yPH/uKOu0r7NPw43wymurKx7muTg/fAZkoIL//xgld38b8K/y0/0ItwNWyCmsHFTgwAwvfmG2ZUCMULcskM0dhAMNVlW7+WOhgxsDHz9/3YQlckwDj2WG9/zN1vAsaY4+rP1icm4hmYnj+hYJJPp/DC4wq9nANhUX7gga2hl+WTvQZpeRR25TOo5jQyKdj+D1+nvP7URGHTqcmipJSt96DA788MuaLGfcZiLJxClG5NBq0aDJnAbMeC9LdbwGeJvBT4T2K/zeQ1ROR1XeW3p2DYZEKSciDB1ba4/1KEadj4FKR26t1ReQOVuGpUcxApCKrQ5fGZ8mae/dOdJKyQqDfN9FWaL0U4lpXHdGYfQQzgiSwpw4wQnNL4tR1aVingFSaR4BpmmHEIoR5nK2zgs8x4Yl1cRaynrFixWqqHIaRurR0Cf6GMdHPYlMKa2q1I5Vl9qz5R4Rp1k4sYkUOI5VA92rNmoCwRQgGlvPgRKWNcd7D0yEumfRmC+3qZ0m/JhtPNIvp71KNJWxohUuMR5L1zo8Tz1+SGLPdRAvME2BK6orIQmqnJyBVW/thFIIlhQY6eXKqWcTnMahkZF51RGSGwb/SOxpYT8fojuDW7nlS9+CDP1NUnIPsLbmo7gjlmCItHFMOIRdR3SvRCoIoOytPOCdzGLkIu+qJVhBQJMFLtE0go5bpdbuiMUvWXrDzlReN3WNYqQitN9siQic4NrgrFBCYw8hFWKclUiU6oXW9hOt8DiMVYa22cH81Q/V+atbtgaQirduj0bnP22UPJynLYaQirEf9Rs8SZtHUezzLLC7U2Qp9oagCgk++KxsjRLvoU8R8+AFGfJCMEUIzFo/SSb5gbLGo0Vq8337mDZmIrtdbXdHo/0FOLTUcQiaiUB+fMu9OG3eymQXMafksUR+cr2QVPni34h1WEUwm8up1Flb37Jj9mQpHzFIohFQkNepdkUKxiBt6cehD/64XEUz7F1J4BFwucltXohXVjMINakNPLKBFMKnIa9ZbIqUyIcna8X22dfLExvkBpExEomOkIfT3RCEtAnPiBLJY27NY4eQgq54eQGaE8wNIWsAIf6Vnj6yyAz1+zHsuZ2/ZFJ4+9kkMFgs6U0XjWg7hhb5LIl1oAPR3q4j2T04c85RE/UH3JTGgJzrWM89Jvlk28aDTREaF6vs7nwqfeG0qac4Xey9H3XWFDhcdOg9X4vWqHNLznksi+0pkmFzjpHvYbQvCB/jD19PuxZ/PCREy5Riiza5wCfSpPCIyZ5gQed8leTh6Qhs8CYOzrYPFzktaB9oiVTghd/wUi7q6zzATnmBQEhs6IiveIPcwDtG5pOCw+5IcXjWxnf9UH51PIp7FpSS3mfDMdBpGsLXxzmUsHXZfkmtGHDcWYaVzVNHnMJULnZdzPlpviCYGug3PsyzmPZdFtmhRpHMQOz/HmBc7L+lUri6yFHV6hHEWcd93XZIjXSjsg2S9C0J6rr/yzqX+jyFRkhQ0RVvkabjJTJMzKP2875IONYXH0sYuONv2uNB3SbuBlljxYV36r0/TVH9eOOK+i788HrHWFa70Ftb+Lp3+g17+chbUa3XR+H9wfIbaqjwGFPr468lvtEVnQx/90od/38VfL/4dYayjSYIEU1MUml/G6uCLfDpHwKUK1u3VGiJyVR/GEE3r78wjWO+2JPrs+Jhr/IiwvOlS6Lrq1UQbNiyMced7t374VejS+U7aDpovSUvXRHN0sPXJyd3YdxK3b7ukHIemMBjFwdLikTgoHrVPTKJ0A7ojcDGZLS/8vn//Gd3jJX+9zqGXqol1zoN3u/N9sdI9BJRKz9TqwhjWBS53UfLd+UoCcc2bLslUFAZAfvQ3pCzC9m2XtBAK3aNGWBZdWctlWbfCVAYnWJU2YIXGS1IjXRFtg21U2pjt2y4pAr4joswm/sYri7RC4yVtNhqi9W4ULUsTyH3bJZ0Zt4SBxs42Km3UCo2XRZto1GwnLm2u7dsuyUXeEZ3/WU4EW7O4DKs5b7qsERN5t4dh5JQ1Yvu2y9nrXDWEfvuvHreA8Ara8CHcCIP0vnc7d6SXcnasDWGgnuW46dI7EYj43QKatV2WjSzM6nc23rYUurKWy6GqJRyvIbv1qxS69m2XQ1lb6CKy6QWfvlMObcXWS6JOqC8/kMD5Ssqhbd92SZRdCYN9AqesQcubLmnH1hPG8YTkoSQFkjdd0p5NuL4ZXnkaZN92WbtR0SmeiVdPr0oirdB4SbvRK5E0YtZnSbMsb7osukR70Y8bZ+ugieCIwkG+98hn33g5NnK9Jz413yYlSWPedFm2v2ieacDQryUJ477tsigT5rBuvagkwvKmS9rTCAMvbLIJ3bIsq7ztcvYvLXE1h8xEKEN/FBovSX9ciebZHDr0ggCL45bglyq2XpJ9VT91dhw+OOVsPQuNlxPoJK4LM9p4q5KmW950WbEMwvw2J6Z3uy+FRQ45jFQOtXqnJtp89skttBB7Ufhwlrp4hf7LqZomDs/sk/Bh566xkKiiut7qTDw4RKIkd7nw0Gi0BHrSTbhxlkripQ9EfMBZHjOOIVJSREtbqMmWUXpqxv8YF/Ie/vI4gl5NmHY/xSZWTpm0iyRg331JET/Ca80/AiZpkn5NQQDPUym0gEBJRWGFUSRWeudsNs6KiBaEPZBUi12vURedJRjeBvMiTyZgfP/A5j2cY06LTGrbW4b+iSwEDiLViMI/wuKKWOs9cslWNKR7ILlIExc/mThxCKLkisvY5UBykdaoi4RRBUPe8cVZ4zmMXIQ1hQW1R7D52mDxElfo9y6CSUZeU1igxtsQNwI7dZOKCrcWweQir9URLQ9TZ5nCsJwKhs2AZCNNpCfHgDGMiOMKKMthZCNM6DwlQfjguc5GtLBlMJIRdiXyVmnEJy6gLTJCcxi5CGsLQ87t0N/gfZ2iAeMgkpHVFO0X5+HtyfHKYSQjTHj0ZeLZzIkZlsNIRpiwyOGQoMcWhkQkinsgyUgTHqAvHH91Uhr3QLKRJtqe9j3Xx+EQLmV7ILlIE98VZKW+F6yEhGUgspElMorZlQW0gv/Jiw1YnX+5iLsSETfZueF2jRnGNGMPhC4RlzY8Bi8Xwd26MA7PT6Old1pvFsAkI094/Dd1bhPv9pTfkcNIRpgwGf0PzydpEorGLAORjSyR/T9IwtWJfU0GIhlZHZFa+ehD34mzEgtiAUoy4oSBkxOCSzPz8ApdboeAspEoGr8pngI/nEiHZiBykXUlVP4mrFw7f5kmzlfxKckhoGwkioXTP7ndyWEkI6whOt3SnOjkqp3DSEaY8Niu7936aeDFjvjKngxIMtKEXhsrPTlkGYhcZPWEUXmW43vuzj+9ABwCykai0HtD+A70RcvcI1jJCBXeSaS6JNlhGZaXjegxcMnIFaY1fojCzanThxxGMsLEVXu/Et+JE7HBuQeSjDRhQsvHBzS1xAVcchipCKvXhMF76LE5uUDsgSQjTVw0Mj8neYH+fAwrGaHCKlmj5ek1PoeRjDBhEohB0OIKN+LqZwUouYhrCOOcjXTjQQsnTtgLUHIR1xSO3MS5C0jspRuFr9Pi2mXHwGUjV3jLECuhJ6Qxh5GLMPGFVxqGFNOlOhugBGtdvGBI7SJc1c3bkYl04TGuCphtd9EJayYHkou0jth/7jlsMTi9MD4GlYxMYSjVIAkj75SC3QPJRdrViQSgOHGCMN7S8nJCp9ghpFRENrpC23RO4nto4kTJ4wKUVMQ121fCIPGHHRqcLzgIfQQpFZGtdlu0I5zikdnmdGLMAZxcBHaFF9JNvQ2JU19soO6B5CJNfFD/AUPenJMbiyKYbOSJb/hOnI33NfSFdmkOJBlpwnXvj3BDMGNadMCUw8hFWE94PZDpRWiJrE44jvZQUhHXrgljyay53UZb/PkNBAWQi6S6kCTT1hq4b3p+qCiAXCR1hJUt1W1ENh6eYIp2BTmQXKR1hbdOqQHecxI5W9yrCRe064lpVGu1llTUderCcqsj10k8+EU0bjmMXIQ1WiLCyIMX05A+AWE5jFyEdRsiC9kIo9OB+XsgyUgTei9Vl7wgBLUAJRtxIj3yh+O/wKdQgJKNOPF94nSruRIvAAUouYi7qgm3a2TrnBLKHEYqwrotIWEqlkWC7k/stItgcpHXqYs0JRZoPGWT5DBSEXbVOnEDQ3QyByGHkYuwrtA/wqNSnBOurSKYXORdCZNHbBJ5L3HdHcDJRWBPGAnXrxreBrSEUJ3sgSQjTVihbkyW6Qk9mYHIRpZoCRjFJ23JDEQysoRHIiNaV/OU8z8Hko000arGQhYexEOWwUhGmPAMYeiHboJGlNhzUwSTjDxhudUh+ipOpkRSENnIOnExOw2wFLu9C1CSESeMbxtsvejUYXgOIxVhsE4LKzaHD6f14x5INtJOXIR9akXry5hTDWQJ662GfhbIfKqc3iGkbEQKE1r9MPAehOGkGYhkZAlzlkzsG+9I3ghd9kUwmcir15ttYUDJPS7Gd8o28jZRCOiGwkTdY+BykdsS5nt+jO7ChIhjnjmIZGSduMJrCxajLy4fksHIRVhbqFSGmJ4kVioZiFxkdYRpBVoauelGrCs5iGRkXQmrb1c7DaG/d4C/y0VRTxjt00/vie/F4grHGYxUhIFFIjoS+ZC6nu+fqiVegJKLuJawWKfhxeHp+14LUJIRJzyI/EAS9HuetiUPAeUisSOshDhYxsQXbm84hGxEiZYydRu6u0Co8zENMLxHp4ZsFUfrja6wLOe1d0e3LcIJtweSirRmTZgvYHtBGHknak7sgaQird4VBuyqAajA1alhK0BJRVyjJUzBnXpJFDoxnvAIC04UwOQir90T19K4hb1mnJy46CQDkou0jjiO1fsKk2kplso9kEykYQK8yJ60vW3kBM69FwmVSQYkE2n1el1Y6vHjhtw51aZy6yTJjibWiKrhHoGWiVhYEoQJ7wsPo6gDZSCqJJjByEVYTejpsMM4u2jiLHX+C/2XRL5wsTcwgjxdCVeMHEaycRVuiT54945/krQClGTECYuxqkvXe/DEIpvDyEVYXRjk9YG4ztanaW7CjV4OJRdxDeGhZR/wSjeOOBVuDyQZacJ7g9ToDoMll8LbgvZAcpHWqglD6qMVoZ0LKeMwkhEmNKixOJsXrLzTJdw4lFzEtYUF4YdhgDdHQO/pgwK7OS8V+ViPQMtFbEdYJP6TE92ekNAMRC6yesKsCBQ9eqsJmEci2g7gJCOwKwxHWZHk9LFmAUoq4up1Yeb39UmteS2hzqw3hPksA5ooe4KuPZBcpLXEx7UuCcIXGCgHcFIR2GqIfZBeEp2ebQUouYi7Ei7m//Q2xHfQvhKaYEUwqchr14TFeVRAMxQWFKQAUpHUaXRFO28r9cMVeTiRPJADyUVaR3x5Ip4DPTji3cAeSC7SuiduAA5QtYdCHbIHkow0oUur7/jJyTV7DyQVaVfdnjjud73zlaUX03ULo9ZOBAA/BZeK3F5DGHXfJw8n1oHCieQ30cVbLosocSWhe++UdH4vWXnbJREmLFytkSgJy6Js33g5LpKaMEuCi4uC1a3LkkVovCTSeuI5Fp88Xf5+ynjbJbm1GsIIMM7WVplj1ippzBotYcZfJjHtMsWxXRJpwptCzChMQhfWKXed4oVe6524nNV3Enmsm5KiuMU3UEQsZFkriUbadknxv8J9nAqIJeuIugiV0WikrMECKUPHHO+oHLtTHLw4WkXZ2WsJdHr71kuKOBLW8SqeLJdAXbH5ciJXGlfiPUNETm30vpe2m029Xc4y0bhqipYJ3VkCUcIdwvfSlDVdTlxfXViwZuinp9093y2IeeMlkSa8/itT2VZp6vJRDyX5WIXxRurGC8L9lRknzjGPQEu1he00hDnxKxJhpe2v4pi4ApRUxNXEFzaoeIbiA56i8ctgJCNMmM46J6cJy2EkI6whPn/24iQ6PWgFMMnIE654NgmIe3roimCSkSc+DwPljQWG7kCBO/6tI862PgCVjEzhncgWil4SfvYC8TAewMlFYEN4hbCN9zlvT6cm5FCSESc8BlQD5y4iJ6p27oHkIq0l3K3Pw9i7872TVdIP4OQisNsVFm/zovDWE2+DchipCKvXhSGLmudjNsVXYUTAHkgq0lo9YShHn8Sb8PSaVwSTjDxh4kWfgLDBYibWJwUoqYhrN4Re2CEgDdsbfxcLz99NGDTZYoQ74nQE1fhnlWUsPL8GcBC5yGoL71hQQT88AFJrcRjtHkou4q6EHhPbC76eDArbA0lFWg9MZwFpHzBg+yFcisPxcyCpSKvVhBlNA+gL1+MTGrIIJhd5TWFsqQ02fhTiJZ3C+jZFMLnI6wrL+GjUxA/RGBbXX8qg5CKuJzQn+/Q+shWWVhIu3gUwqcir14QVpkZ+SGVOVBOSg8hFVkNYdHWwZTjjDaRChbIHk4q8dkN4BPYB3j81bDmMVIR1GsLTWDNy4vSEIslh5CKsJQx30JwAUQ5Fqdc5jFSEXV3VxWsbVpyOHfHCxmFkI0xY1sxznZNDtgeSi7SeMASzT491TqxnDEQqsnoNoR3ygWxORiXmMJIRJqyXZTpRcHJTsweSibR6vdkR7dcs4pMHGJE74e0fHEYmwmBD0xMRRra+d+8EMYnEJ+QHcDIRWG+0hSVusAj6qbrUOYxchNWEFWA+fnVOWCBjN1FqVzW5LlqrNYXltmENdjbQiPiKBVFIxnq3JdFnxycbendxkbRC4yX5NIS3R1hbLwrBhIdGvj+iRkDeYfslpVALV2x14/lY46sE4vKmy4qjESmRiefj4fGJYkscRq7p1hXGzAy26NFNxLp/DyQZaV2RNaL6dFvprISHWQUoqYgD7S9S/vPTB1lzGU+x6g1hvKFF7kPYgkWOUB4LUFIR1+oJD8ZtEoMO827FS1sBSiri2uJCNaNlujp1F1kOIxVhV1fCes0jN4ydLQGsCKb4icg7hJSLyJ7QOTq6peUwxKpyDyQVab3GlchnY0cOBvaIz30YiExk1RutjkiZjEnCd2PCC7syIKlIa9aEi8Acr9E5VRhqDyQVaY2uMOj8Q5rs/O06WTsngrYOAeUisSY8UJg6t0l4asbtgcon7enTmD52Hd+FPhKyquLtnyTCTt6/e3P8Ob5BHuCbtwEN7/iH7zz3C3sLOg7gOQxkgI5hEsUc3yM/5eyKSBymkYuRqOldjMkEqxT2830ncZbIqld9s//63ZscLHuv0FS93sUz8ceNI7pH+z36wyMifC/4zCg+eIAwWydZf3F2+Gv+sUIpydiO6BaHIA62VV4GE34rfst+5cUyq3QIiw0JfsR3Eye6I0nGZ/atwKL3HwYYcN/AIvKidLrqaDR6JMZhdOcEXrx5f83SRvLvGUABjYMn77dhgkx1EjyqfzTH3jx6C5h2i+cULjloCKTK9YuP9g+Lz3Aw0uUGJBiI69XxnB0I3T86BHW9xGGH6c69FyvzC2XopP4qVvpvi2VIcV546eZSUZWI3HvkC02VS2Jlu3aijeOGfni3g9m7UlxaUd/xlTTGuqZ0Vm/hHaQ+DChIAsOV4HzBRhi3QwL/Y97JyovDCNM0LhUm++qdF9xdKvVer6uo2+i3eu1V6/XbRq9XbTYaoAhyAopseXOELyd5ddWtdeu47p7k1TDarWD8FfWtYoRfquhPR60RVb8Q726dKGtW8SJ+C+QqIchpxjFghhflPFvtArzIKr7In3yGbTYgGVM2bWABR6bEG+QjTSMCrlw7hBasjr2YcqXzW6OjWOl26yuNt41WtXn1cqbkj4pylsDsXoYhnej7z/vfMyWQz33W0lOZffc5CL8EVS7sOxK/e3PwJAPbhv5uS7YYMMOn7Mmp+O4OdkgRKKDbNHD5thDPpqsJtKQQvPqSNuhQGVx7Sw/mXbac7N69efI6azXeEhf0nrt/PkHftLfZhlGCCxI/Ad9ictdh2zBCGPK5cWCMnQQmyR1dRmIq/0s/DGFmsHWNTgPXiV1nRWA+2Uhb1lCsZBRfKGjiwAIH3VSbb+yJObes7oXixMoX4vv49y0e9UWxMvqnc6H806Ey88+Rc6mMoJ0cs11ONtYSvsOp5++ARWsHxmpVmKExDh4KKZdeEKOn/Nhzv8r27IO5OZpqdcbSamGE/NBN4/f1PxvN6p+N9iVAsCfsVxdooDPGx+xwNoBgBsC6C8L75DeuyGHPH29AUeDeH1T+HV8Njj/nI+rd4TqVPaxXMQb20UPe+pqEEU4+XMS9951LTJ9/9JBBPp7u72F3XKtf9vAQ8clvnFwc1TAON2RPFHDk2GP2gnihEZgVYsOiaFpc/0P/qOh40jAFBAIXJDONiKKFm42XJASMjGt9qh2xMg7tDAR6S6Pdj9gxzxkb34InoKgmMLVOIbIXxfIQ+QBGL+NZZoqdwmrSqHfwjuKSccrSTV+KVr3bq3dKZFWKG5ckVMyCeXAKp0anWR6j/hF4yKPxh1NYmLV6DZOKysVDUV1YKWMP65SK8VGndvO/r/8xUaffiNPzBj3qxV0QBrvNXmnwB+9VuwkKkn95+iNdh5/7GdbgLdbBqD8Cyb9mvWPV/7CKdxpUY/JnigvP+/99l/zmu/6/P1iDGV4uUGs3/v3YBKhMbqzpYqTbC9vSx/Px4sYwLMMwRvrwU19b2Nq1bpmL/kiz1bE574/MydScaKObuWUOxpWxag/6Ax3aH4/MgWpP5/PFp4FhjdWpNR+qtj28mV0bat8aT/vw72hoWKZhjSxbHaqViT02dFWb9m1jNjMmg8VwPOzbI2swtq3+bHQ9HA7VsTHV5sbNHBocW9bYWFjqdG4M9Up/bBn2cDqwb2Z9eMVY3OgAPDON/nA8mKqDmTVX1dF0/GlhTcf2QJ+P7P5iZFoDeFgZGPbCgH+n9uhmONaNT2NrPASCpvZ8PDCGN2O1rw8szVKtyeRmNtDHw/kNUKYOdHtWWRgDw4S3+v2RPVkYI8McAyssQx0vBvC2bQ4WxmzwyegPjMFgMjEWi2uwNIbz0aCvV4aWMR7MjFl/ohuLvoGdQt+GqY+w9Xm/b9wsrL46vB6rQ2OwmA6QuaqqAscWlcVI1eeWMTWn84U9BJbMzaGxGI7mg4VpAC2j4UQHLKemthiDHXpEIgq2hkBKmk+kRHmVLQWvK6qt2zCymqbiJ121VV1XVQ2fqppmwwf4Cv/gX7pu2wCswZ/wu6ZV4C8N/9OgBR3+puA6vq1hWxo2o6kaPtM1+g1/xRZ0rQIfdOwW/tApiEbxgD+hK/4B4FTsE0HwkYYtwSsVREajeCJm9E+KB+JOIWgLCI19YDf4DbGyAW09o5H2T7GgXSMJSA++gB81pBYQpJTo2LBdYe8gt1TKMxUZhUjaGbmUUlWnnNIo+Yxjml2hb1GaEQd4xBhN28LXNNobJcumyNuUfBUZX2FAKm2XskHlvKRIqjZDmv1nU6JoQ3Q4KhoOC6WHvkh/Rgib9Yo9MJTZTwCmUawRDdozGxM6FtADxZmOMKLER1XVKd02RZsRAEJCqaWEUcboKnufyZVNuarTHtknOhw2x67C2MTEU6Ud6mzEqIzQr5TpdPhsjUopfx8ZRmUCeUwlk0orEsoZicRwXPRMOlVsDSXMZqzgrNZULZsDatYge5SPFb6p01+AYXRgqHToGYeYxOLvmk6nEcojvkGboL+i0OsViifnpMa5jaKgMzmxGfK6ToeOTkcEo4RTmlXKRyqxFENbZQ8p5kw+VSpbdPJSaIZERWdzj4meqjP8GefoGGC3Gp8n+Kdqs/mHpDCGocDQrnBcs+YptlSekEVUZAvcZdzm4kpxo1JPqVfz0WbEMxHWbTbVmXYA2aaywVQF4xxOKkoLZ6xOP+9R4hpFx1mFRDIq6cDgc0RFYzOEyh9TBpmq0FRGDPZM5YlqRZVzmeoBNu9URJYpTM4Cyms++SqMITqb36rKd4iPtPv21ikYIfjtGatsWKvVsBrpUeuKu4/R+nh0YPdm3yT7nJkgd2EVdjxggR3unQ4eF3rAEmZ3sJl+74abbRgADnhWzJ/twYqn0vw4INuYHjmyRpyOdvgz0aBV5rIttRLjHdxyoEIe6M73XMiwM5mN59IjTnoKJgdf2LHEz8UlO785iUr8TcdoZ0ExP3xbYgGp4O5MaPBTsnKwwNspYHt4Egl+zIgniuHt02PGCxi1BA+iPVfhXpnz4BmQO0DoniiHCHvBre9sNg49poRtMMyX+CfPwh/E8HAOlCP5Lx9sxiA8VwlSGFeqW86ByRNBezkajx4yh92bpy6AN0W33XM+PCyO+dSHZ1bx6mMYqsfGwPd773Ll91f67urdTqN3hRGcJx1SlrcJgRKlf6Fo68iLE2V8oag+BkhYF8oHkGInVvS3inp76wXoCkBfQe5sAjlfebcU7b3vKlNs9BSvSl8wcsZeKhbBQgk23XYr19Qldak0wEZTfk/935rNV+3Xb9vNVrX3U1109U670W5jyM9Jlhjp6ot3p8x/LzICq2158HkOn0OyDtzPRPl0faGMnfQWRIL+cE2C2F37JMIvuuf7RPn9rYIXOjpLz+f3OO75dRtGm7jgNomRYXG6RY9KrOxlUclWFnS53OOdujCBoohwL1HIfYMFv43rgLFG+wuYal+GEcYFksRh/j/W0n14mY+Dsx+IjjJxot967VdNHIh2lVZQltAvmAb067f5Bo9P8SNeQQ8LGtLbU/cL9Yudf5rzqvF/XldXZAsTCMc6Ii4Wwopw0JXNjvh4YwMabjHz+mEXdCxdJ1qG690qooML4xcQUNjhdu353LcbBqG7gx8vlQlZebmnsBCoQq8LxQUHo1HoQgQAPhDEewQUtig8PklidjWoT9LPWasor753h33R8mSB9xW9fbESQws7v2qQL/Dln4XuaRycEoW+j7MeOs+b2z+8h1lx78Qu20uk0S2YrbGySiOqKCj+XoIoxgnZUvnMl3ikCE/p0rv1AZUUc9PSjfoLHY6GKXA2NtDZeMrVOMm3ZN/maux2G9UuFnn/Jo8jpty+0OPYeqnHsVe7ajYv67X/uR7Heq3bKNXV90KfI0qjVP7GTq3RPBL39ZNx+mZ/I8jr1dHjm7/Yu1fv0FvoZPHuGTfq5K9072n9ToMGWYIGrfoemD+3zsbzd/SYCpS7+bx3T5+Y1ToWtHgeYC56HXRlirnaXG2yIBoQIXGb84mgTWOgAfsEv2crWPXx8qk4qzXBAVK4/iSKoB0TXWwTwe98Hc7Wa2x3bzXcMcqr2Xg9YcHPcJc2m/V/762iCsiTNhupI+NmNh/O5ovFUB9ZM8PQhpZqoAvSns7Gg4WqfrJvrm8se6zeWJ+mI2s+vtEqs+n8xu4bC3U0m46ng1H/xpiOF4Z5c2NZNzefRvpoPp5Ox/Yn+9NCt8djFVobqIPpJ7U/rQxM+Gk+nQ762mIwuhmNLdNSTX38adofXGvGeDy+Vg3txlYtbdafWJo1nukDzRjYI31aubE1S7sx9eGNbg60wc1iPtD0AfowZ9cLYzLVrGvT0KdDazi1Zpo1vNbsvn4zW0x106qMQRwM1dJHn+zp2DRn8EWdaaZpoLt3rk8ntmZcW+pYHc6uZxb0PLS0wUAfqsZCr5iDxWKmAVb64pOtmqq50MYqPJldGwPVtAa6PQGCoHf0Bt/o8Pp4ONBmpn4zX1TmutGfGHNt1Lf0609ArmHa2kAdQfumMbDMxbVuwevACWMOvd/0baBkONdU6L0CL+pqf7SYa/2poc+y3meqAb33DXNhAnPnC0r7UFeH85uZtYDXbW06qOiGAdir1sJAcm19+mlqLUzg3UwdmZptGoZlzqaAvK0tZsA6C0ZwbNnabDjSKv2BfmMZFrB6bvQ1e27p80923zLNCSI/1syBMVTNwUy34Gerb8/1wXC60OH162HFAnT1IfBchwFfDDTbxtct1TaB9rE+Ui1ggqkDXibIB3yaARY32vz62tQr9lAfTm1buxnq2lTVh7Yx0vuWbVjaHExB5MHCNlVtri7GGgjr9QIGdKTi+E+NyicUABiCERUAQADkeqpb6sxWtdlgiiNg2wvAYqbqMF6j2QAQgJ50daFWLJAzYzTRddswVMOYj+fD+Wzc7+tArjE1r61rQ7dv9MXQnqrqsG9a5vc7p5vNRmFOolvaMKlLmnlIuBPT5i49O/OloeuHuwtV5ppifkp4WrGZ38bWuCuXeSWZp8nOHDM28y7SJpiPiLp3qduOOShV6lNUmfOXOUxVm7rPWEfU1YT+Ioof87BSrzB1H2nUCa1Rlyr3Z7JfVZX7pajnjDlTqauS+umYNxX/YD3b2Wfs06Zea5t6PplHkntEqZOU+9i4Z1vjLnvNZg4/eKRzVyVzX3K3JXOSUi+uyj2uzE3IX8g8+ZTjSCd1rFJPp6YzP6fGXeMq854yJ6VOna6azT1wjH3cX0gdXsggfJn6zHMHss6+Uncw97fqbPRsjXmbqdcUEazQNljwgcaa1DibqIeQcl3nMQ2IOXVNs+aAZs4Hm3mI2SBoFIgNMRM+lcUOaDysgb4BPVO/OJUx5lmkQ8W874xwGvFgM0c/c0Tq1EOrc2c4Y5RWiJlQVfYXE3eVcUalrWNf1G1JJYy5enmIAZ8HFF2dOdQ17ibVmd+Ytk6HtcJ8pZS5dE5ovFk1mySMVTSSQqVzR6XySwMANOZZZz505rXXGJa6TmllyOvMt8z+pEPNemaBHNSRn0dTqAwu880ysWWzj3vRUcgq3IHPIyjY2PJwAta8zVzlOu9YZ/OPPqogLYzPzHVtM68v81trGcs1pkKY/51HTmBwCxUZXWNzXWdfWQPc288jSHjUgcpnKbZbYXPeZkKHbmXK4izQgwfYZG50m7nieYCNVmFOd5U54WmIg0pHQtN1HqNDZZexPOO8yhhQ0djg0jAGHs+SsYdpQArA/O2MQE1jTm6cVWw6MAFj/VFFqnJ51rno5GLDJiydMRXGajYhmSbiesHmY5LLvMrDirjoI8O435xPWh7OwMM6qLRlCp3Jjc0BqbKqZELP5IaFCfBgDpuRS1VvFsJgs3gfFoiAwS1c6FUeOsMFI1sdbD6wVP/rXAUxOahwRa9pPMrI1vk04kEofMKy0AsmwjzOBQM9mIrJmqeLk0Y7YSKm8kAbO5N5ri3tTA3pLAiJRxhlukXn6obq90wt02Us0zYVGjzBZiOlKguRYsqChlJwRUFFlMPQqQ5TUmWqOhsIqvk0jQc45DPZ5kLO2rGplEHPbBx1pkOzSCudheKwMBRKUabMGUNYWFolk3QW/8HEkMcj6Twci4PoTEEzdUfBuBpiMUc8Usxm4mBnSpfZGnq+ANicKyxkLFsBmDzR2cT0NhtajS1vms10KJc7+KWicqXFR0HNsNJ4zAizEZgaYlhpekENscmgMpFkmosZFFyHsvgUzj8WdaWziJ4KjVJiQX12tuJnZoKWTdX9xKILNVdWaoVbEWxN1znnmIrkcWNqtkTyqMEs6gvtMLrK85HUmJbWaCAP1Ys/Jdzl6ugxTnYEbqXx2ns+2uV0821hNI1Bbdb/fnxf3hnjaWAfH9KYmnOFafwK6DnCEXbuAWIUk+yg4+wcytFy/O3akQatIHV9cl4Rzo+gYszPCG8VSWQaHUIwTL6Sv1I6ci8O9Al97y6MHdddO1iB6sxhR763DdEpKg1C8TEX639eRNaLsbjzd24Yb9eAAUjO9uxcuU0BnZKE5PvC1Nhkx/uy8tPy86BVWL7YGnFGXPbOdlzaqwc+ivNgJAEK2zD2jgTlbdc4wfCGhZ2Pl1Z6SegrzSq/n4z52s8m6/uBTEiyJjQyIoyyEIq/Xbzez1UD+wDGp+vYeXBakVtquxZx0yNnU80DQpegpmAY059stL14GrLKG9UNi9NZ7eVbSWP8E0N89/sBDq4wp/N5UJYorHf71DMrlSrba4uNB2uQHHOThf64irtz0bSjNnkarKRinOwDK8Hq+RQhnncD+uLeiaUwds4s9WsCqp2GZaKcPzG8lHvPebwLfSZ8JD5bCHyjcyQEPgqTsBoGboinkIpbHYbx3zwYvtdtd+u9zgsiv6fO3U7540KxYQWMvc/K4kL5ANz+HGIEPMbFsjpjOCmMyadr5dW+ztVrjNVN0g3G1kZYQJcGcV0qppOswcb8CAz1lTnG1zZqtZ7SJ+5v9TbWo+pc9aq9xqWyCr23Sr12Wa/Vum/ieqPRblYBEn6rtardnxsL32t06i0sx3c6PSCNQXyQEb87QezQKl8RhvFNLpRr5w5kECNaVwpGwkdfnQCfj+7oNfD4xPH/VWVfF29pqSnOF+RgPi1oJt09TAqXK51qFeZOCIBL/0ldP+gLn1SfsLowNlkZIhg8tF41GvQ8Af73vYz/E2dX/T0Nfms1MMq90WgCiwtDUO+8+dfl0t2sLhH6slaH/2CMBsCv7P1Iaf4nhcWfmPZPA+RtjGTOtJbjZ6tpIcvvQokCHEh/t4FXMRHQw8QFGryGF53S4XvwNvAyC29WMp9HNYvm/o7Q+ymelToR3+qFWazgl7XnrnnKhaMktNjaMk2UAMTNDe8dnwRY3Qp5TVbUcPHJAwsxx+j03/8xfaOa1bqSFMnmhbQulRGrhcUWhZUH9MI8+WhRcc1fXTqYTccjuRXiAD4xIRsa9p/FtbMe491mQ5KIFsPrT1Vl7fi3YL3T8PyPgWLrw+qSJE7BgrnISdukfoIIQFfWRO033+CfrTeIBWKUUeYkFGPVrFOAapazg70gQlkZsryzI9sILCmHXQI7aNj5QaJKZkPw8P4VuSd+uM1q97FEBFj3sDz8CjtE/FmCgwPMcHh1sfgzmmqoSEcJ5iCAMk1x6OCFtXOP2qFQYy3CG33gRYYgGyqsfkn5QxdfkAaskc0MB9pbno7j0Wd0KO+i8AviTZG8yFMp4kym2OFcvAsSXMqxCB9TVjtlucvHBN7X+laddmKOWuOGiqkVQEJeVC0CafdAeyn2LsJUEdZ4tPP32MFKH7oMs70s0sxCet8sSlOCajPdvCgFAgTg2QyI1p+N1mXzVAIEnV1pXGqptZclPbQu2y/NeWjVOr3W5VX7G3MeWv9BSQ/Nbq9z9pwHKn4ypTwsavV2Xb4Sa41er1ZeIsa31DMDY1SejAcQn78y3yHb9eZG0S2aRM+mG9Te6HUlBiUNyzpf+/AQK7M/uqJXrce/fkcgf63RaNX+fcyOq0wmQ0sfTtX+zUC1LGuuWZZqmaretwzr5uYaPvatoWVNsATaVJ31h5rdN9QFQE2HlZFpL2x1ZNmW2Tdmn4zFzFQN+G2hmtbMnqsmxpYvTPim6uqNNVf1xWJsT2xdn6uVmTXS53N9vBjMDMscwD/j+Xw0nw/m0/FEVdWxNp/O4athY3U0dWD3Z8agPxhbqjGr2IOROjWM8QD+NQbDkaGq13NT1cYjs9839CG0NwE0LKNvQG+GOViotjmwBgN1aFcM0zCmfXNgjk1rMTAXY2sEFA6MsT0wh/3+0BiawAuMGbcGtjq3FmZ/0jfg2/BGraj9TwPTuIZvhj7RzYlqDwx4oNnmYmHDn5Zmqze2ZQ0XQ/vGHCD74JmK+I0rGCk/HZiWhey1TBot/gOR4I3G0UFVXsF0oCHhKouQ01hEJ4sRo7F3PLZZZ0FmvIwXiyKmBZYqvHAYDUDTWTQ5jQRnsdVaVhRJz0L5bHsfOUaDGjWdl/bCPnkkFo+s1XSdFwfTdP4aj9xigZwsmpIGdvHYPRpDyEIps5e1rAATDyZGXLC2EG+SBlvrLHLQ5miyGMIs/o6Gn+kstoq/rGXBroxfeQAfxXUf7MvKrVGSeJ0ljLllAYo2q3nGAwpZCSpWX83OapvxCks8jg1BKiwKnpXp0nk8uc3CyLJx0Xgomc7LsvE+VIz21VnxMxb2RwPfaCgkJ1ql0XUsJo3V6rLzGNeKyutEZaFzeVBtVv1K5e9n0cWMPspCWh+NhU2zmlU2Txngw8tCdbWMVBYjyuO3cahYdoHOYutZNbGsypbNo8j5ANl6xmwWP1thvbKBZqXgWNGxrKaXZvMo36yeHh8dFk/O4445qYwFTCAY8rwsHUM+i8RkUb8VLnYs1jgTPDsLPuQ5BTS6j0XA87lBAyorfLrw2n5ZcCNvkfGMxQ3qrJSfzgLaVV5ojGcOsIh5TeMlxhiJWR2wLJ5eYxkDNM+DVh3kH3n5OS1PbuCzN3vZzip+0QGg48pjbvl/LFdBy0t20aluZzJBZ66WlQZDtAHkx8MW692jxkZ2RLH8Y2T+d12eqMJzRz5JEBR27DAkO2E4K1vSbzhU/7ndH92cn40XJI1gYMAG/Rdxf76v5NsicGO8q/4sgUxHxXR/Svn01BHP3M4be3UC5TkgWDhYHY2+/2D1LOTRcxU8JDszHj/OR8lE5ZmD+L+7vBydDmcWnSqem0vFl8KxAx/H80vnKcn7C2fUS137cYIuxeq+gtJENcfZvSvnQYmKWnaUdMS9cf7IH1mi8g5DVx7pDRC6I6owk8VzhbwF6GbzNps0IGeOeUtC32e1XfJ6ZfVaIWzwrJVAi9KWwHLlKnG6jBO8jOj8CLmhf6Yot6FbJdvY86n+54MmyYgdEaeGLLgxxzKW1Elj2DAy9/AjZ/D5xQq0QoilI78yjcZWpvOjhTcnnh8LDP4hMUZc/OxDmB+M4DxYdS7QoKkmZEPjTs+kJI7MxKYsM7FQvnw/tuxaTuBs+LC7IyD5aB1+S6jkz8TwlsDWiN50BwwLXAnWP1fF4maSSFJLFkl6LuA78qobD+2+v4E5eGhUYNBgeFYVJ1NGxgu0rZyDemTStGWZNEfVb5YLdDYjCA8BNiRZ786ZdeaGwcrDTxih6MA0VBy8OVoKy5CbrWgRJu5aGrHuySLWVCtgTCliggGdyTo/N8TQWdn2Ss8oN1T+IfaQyLE5CUh0H6axEu8AsU0xqlcaEZRkQI/q1UcVWBJvk/o/21f5fad3GFR9Xnwmu/7VVaFkvrxDG/uEbKWRd9uY18+DjHN3tjP6v4HRx+TZC/4OEl3UBXeRc76bio7Ld+f8XMEIBrz2RgavhtBndjRD6cz3Tx1dC9dgnIFpfeZVx56PhqUtOj81X7fVuTpyZdVk51LHYCE+OK8N/ytr91fW7q+s3f/grN2XTf6/T+6ufWzpKtyPhcscVv+iWbt5P3j9Gibc7mjdxjhUsl8c39/t77Bi12RRIjJclfZ/VTVV+7+6+v9svdr8r0tFzXM9EfhwKQUZZQcJVXb32kpBwuIXZV5ObrTnMi//PimXL863vLqqNS+/Md3y6j8o27Lbbjclyd8rL+vzm/P3YA78hfl7H66N60Gz93zanYZ2mTLgafl4w88DiF24rdKPebSVqIkniVmgkJ+HPqrdtnh12w/n/l21W7V/P78aVCamMV1YQ3s6n970jf5N31rMzJvhjdYfDAbT4c0M/7EGxszERL5Bf/RpPB4ODLyHxawYlmnN55Zu4DU0Nwu8YGVoGXO9P+1jFos1tGwV8/YmCxte0fX+ZDGdWcOR1jf7lf7AHo7G09FoNOtrk0+WPrQw789YWIOxoVo3M1Wdj/uWbplTU53r13hBjW1Zxo0x60PPAGsNtFHftBaLoXkDZPQtyzLHlqZaM/ioDi2WaWdYlj2AX2bQ0sA0FkblejDAG2Vs/BmonA2Q1lF/sbAWg/F8hjcLza0B9mypOnQ8Ns1rC98cz7XK9cKyr2fX0xtVNU3LBhRvTEB7vhgbwLv5wpjPRtZ0Oh9rtmXOoQsb+LgYz+f29bSyMAbz2Xw+HUBT1nCoGvP+bGQOjMF0Ohir5nixGBnjsWqrNyMDBkIF5MZ4tdKgbxiVOTQymBnj67EBf82nQOl3Zw82G52GQCyUVzAlX1d4RXn6D7ugg2VVsXtg+HUWmCZELwSws+w6zDuyK/l1BypLlqM12GlulJblIGr8vgR6ZQO7NILfDMNvGFDza0dY3mExE4km3uUXcvCERZ6kxV7mSVisSrttZ9D7C0GyjCr6F7uposLzubLq8zSTkV8rQxPTWM4VyyBkaVvsRg9M7arQW0UoHjSri2V68eRIlk+p8kQrnd8nkOWf2TSTL6NY47/xrEU7u3pBYxXhddZNXskf8yZVdpVJIV+NXSZg5/XtNZ4MSunmJfJpXljFZhcDqTxvi9+qwzLEWP6mytPd9CzbUs0YiAzLMtU0nl3ICtwzStkNRLaeXaZBcclQ4D3TcveMNi4SPHEtu96HSxW/qIAPSkXlN4po7FoVmubHu9X58LBbd2ijKnvAbvjBnulIsSY0nsyakafl2XY6p8fOR4ZescKuf8gkkt+MwgWW3sOTZVxm0qexbFxa51+zs2lEs/DYrUMstVJltxqpPO+RXpig8cxZeg1FzmqVXbOQXymQ3Yag8XRHlpGYpdjSWzwqmppdasFSgTU+gdlNPOxSluyuBD5R+PU2NuO2nV2gkqGYJ0Ky5Ep2DxK9b4ldoMHZWeF3NWk65yCf2Hlypk4lSmXY6fwuEoqfSu+kYXylE4UKOp9Y/Iobjd25xGaLneWNUh5X2LVPPNWWXZ+jMk3GyGQXTKk5W9mVTUwrVHQ7u0lC5XezsEnDVBW/+4ffxkHTbtV8Zqr07iGb3TCkqfzuJJXfH6Jn15voFPWfcrdDXZgkCUbP99/s0Gi2hBdHwEpSNf74/vbrtfZRc7TQ/n9P5UnwPHMmYSk5c9+aXvrTz2W/4S4GbqTIkE9aRprti1NoBtVl+HDmNJ5HgyFV2pMU6WARYaekzzlgJGSY3Bmwv1Iz/x6pmWdP1zvqXESsVs7GuTu3f3F/psmLY389Z0DjMVadL5njmZi3DYlBwNe7TXbj9kHVRqlQlTDTQzqM5JC1/FKGwwG89ZZRuKTxlRJI2fkTjY9qiH8sfsXwvgRfnqtE0caatFJJuoRZ7c9g6mxDGNXEo8fW7tkSHguqQRKM/r4JMM+MNE+6vffOfFcVXldCFCeCGXKmSYs+enfNLuW5D/17mJ+w204jLCiOJn66UjZhtF1T/03snUkAMY7jjqaBkeger8VMnGXon3taPCNcmzBgN4VIkTgxDbEwrCQLFXUCkocsrutc11MFYUDLxn8KElk4I7qTRwID8dkdU+IEZLtGVeE627/TDsrFRCIvINVkt+Wl7WmcGy5beaX8ok6UZC0+XHS9wOPaRc719xnmy7X7OcRNCh31yNAifggjStgVFSQ4X+mZff28iGzCFTnfBZHPLL5/A5v0mTkh5SniM7iSrZdgtJpEaj4/QPCw8ijiuYY5E8aJczar9TC5qXCKINVYsnP0kN0qc/bl7YBnWP9BiZzVt9rP35H+kn1msCT4CuoCw5OzTxVKTBTR5pAK/hGf5+cu7LeDrxXAOkrv3v9/Ibtnrw==","name":"Nadroparin","clearance":"The clearance of nadroparin is 21.4 +/- 7.0mL/min","metabolism":"Nadroparin is metabolized in the liver.","id":"DB08813","indication":"Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction","drugbank-id":"DB08813"},{"xml":"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","name":"Bemiparin","groups":["approved"],"description":"The risk or severity of adverse effects can be increased when Bemiparin is combined with Treprostinil.","id":"DB09258","indication":"Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.","drugbank-id":"DB09258","unii":"P59JKU02CE"},{"synonyms":["Reviparin sodium"],"xml":"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","name":"Reviparin","groups":["approved"],"description":"Naftopidil may increase the anticoagulant activities of Reviparin.","id":"DB09259","indication":"Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.","drugbank-id":"DB09259","unii":"5XQ9UBJ16W"},{"synonyms":["Parnaparin sodium"],"xml":"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","name":"Parnaparin","groups":["approved"],"description":"The risk or severity of adverse effects can be increased when Parnaparin is combined with Treprostinil.","id":"DB09260","indication":"Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.","drugbank-id":"DB09260","unii":"U6K360XMIU"},{"xml":"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","name":"Certoparin","groups":["approved"],"description":"Naftopidil may increase the anticoagulant activities of Certoparin.","id":"DB09261","indication":"Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.","drugbank-id":"DB09261","unii":"V72OT3K19I"}]}